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ABSTRACT
HUMAN MAST CELL TRYPTASE ISOZYMES: SEPARATION AND
EXAMINATION OF STRUCTURAL AND FUNCTIONAL DIFFERENCES
fay
Susan S. Little
Tryptases are trypsin-like enzymes found in mast cell
granules. Although in vivo substrates have not been
positively identified, tryptases cleave a limited number of
potential physiological substrates in vitro, including high
molecular weight kininogen (HMWK) and vasoactive intestinal
peptide (VIP). Purified human lung mast cell tryptase (HLT)
apparently exists as a tetramer with an M, of 135-144 kDa
by gel filtration, whereas SDS-PAGE yielded two bands of M,
29 Kda and 33 Kda. Tryptases are resistant to inhibition by
most natural trypsin inhibitors and display some affinity
for heparin. The existence of tryptase isozymes has been
implied from the cloning of two tryptase cDNAs from human
lung tissue, but distinct isozymes have not been isolated
and characterized.
This knowledge gap has been filled by isolating and
characterizing two electrophoretically different forms of
human lung mast cell tryptase, designated high-HLT (high
molecular weight HLT) and low-HLT (low molecular weight
HLT). These two forms of HLT have been separated by
chromatography on a cellulose phosphate column, with the
high M, form eluting with 10 yM heparin and the low M, form
subsequently eluting with 1 M NaCl. Using HMWK and VIP as
substrates, these two forms of HLT were found to differ with
regard to specificity and rate of cleavage. High-HLT
initially cleaved HMWK at a single Arg residue, whereas lowHLT cleaved HMWK simultaneously at multiple sites. Both
isozymes cleaved VIP at multiple sites, but differed with
regard to the preferential site of cleavage. Low-HLT was,
on an active site basis, 25 and 2 times more active than
high-HLT on HMWK and VIP, respectively. In addition, gel
filtration of the isozymes yielded M,s of 125 Kda for highHLT and 28 kDa for low-HLT, indicating tetrameric and
monomeric quaternary structures, respectively. Both
isozymes were inhibited by human secretory leukocyte
proteinase inhibitor (SLPI), but not by other trypsin
inhibitors tested. This work provides the first evidence
for the existence of distinct tryptase isozymes, with
supposedly different in vivo functions, and identification
of an inhibitor that may control tryptase activity in vivo.
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CHAPTER 1
INTRODUCTION

Over three decades ago, a tryptic-like activity was
discovered in mast cells by Glenner and Cohen (I960) using
histochemical techniques.

This activity, subsequently named

tryptase (Lagunoff and Benditt, 1963), has become of
increasing interest due to the ubiquitous nature and
biochemical activity of mast cells.

Tryptase is a trypsin

like serine protease found in the cytoplasmic granules of
most mammalian mast cells and comprises 23% of the total
cellular protein of human mast cells (Schwartz et al.,
1981a).

Tryptases cleave peptide substrates on the carboxyl

side of Lys and Arg residues but differ from trypsin in that
they have little or no activity on denatured proteins such
as casein.

Tryptases are stored and released as active

enzymes (Glenner and Cohen, 1960; Alter et al., 1987), which
are stabilized by heparin, a component of mast cell granules
(Smith and Johnson, 1984; Schwartz and Bradford, 1986; Alter
et al., 1987).

Histamine, another major component of mast

cells, has been used as a specific marker of mast cell
activation.

However, histamine is also found in basophils

(White et al., 1987), and is cleared more rapidly from the
site of release than is tryptase (Schwartz et al., 1987a).
Tryptase has been localized specifically to mast cells
(Schwartz, 1985; Craig et al., 1986; Schwartz et al., 1985
1

and 1987b) and remains in the vicinity of release longer
than histamine (Schwartz et al., 1987a) and therefore has
been proposed as a more specific marker of mast cell
activation.
Upon mast cell degranulation, tryptase is released
along with other mediators into the extracellular milieu
(Schwartz et al., 1981a).

The function(s) and regulation

of tryptase after its release from the cell are not clearly
understood, but in vitro studies have shown that tryptase
cleaves several biologically significant molecules.

These

include complement C3 (Schwartz et al., 1983), fibrinogen
(Schwartz et al., 1985), vasoactive intestinal peptide (VIP)
(Caughey et al., 1988b; Tam and Caughey, 1990), and high
molecular weight kininogen (HMWK) (Maier et al., 1983).
Human lung tissue has served as the primary source of
mast cell tryptase (Smith et al., 1984; Schwartz et al.,
1981a), but other sources include skin (Harvima et al.,
1988b), pituitary (Cromlish et al., 1987) and a human mast
cell line (Butterfield et al., 1990).

In all these cases

the purified enzyme migrated as two major bands on SDS-PAGE
with M, differing by about 4,000.

Interestingly, purified

bovine mast cell tryptase also yielded two bands upon SDSPAGE (Fiorucci et al., 1992).

These findings have led to

speculation that the tetramer observed upon gel filtration
is comprised of two subunits represented by the two species
seen on SDS-PAGE.

3
Mast Cells
Source and Distribution
Mast cells are derived from bone marrow stem cells,
migrate through the bloodstream in an immature form and into
tissues where they differentiate and mature (Barrett and
Metcalfe, 1987).

It is thought that all mast cell subsets

differentiate from the same precursor cells (Barrett and
Metcalfe, 1987), but that basophils develop from a distinct
precursor (Ishizaki et al., 1989).

Mast cells are widely

distributed in the body (Metcalfe et al., 1981) and are most
numerous at the host-environment interface, such as in the
intestinal tract, skin and lungs (Malone and Metcalfe,
1988), but are also found along blood vessels and nerves,
and throughout connective and lymphoid tissues (Metcalfe et
al., 1981; Friedman and Kaliner, 1987; Bienenstock et al.,
1987; Stead et al., 1987; Bienenstock et al., 1991).

In the

lung, mast cells are most concentrated around the trachea,
beneath the pleura, and in the connective tissue around
small airways (Friedman and Kaliner, 1987), although about
half of the total number of lung mast cells are found in
peripheral lung tissue (Friedman and Kaliner, 1987).
Morphology
Mast cells are ovoid or irregularly elongated cells of
about 10-30 pm in diameter with ovoid or round nuclei
(Metcalfe et al., 1984).

The cytoplasm is packed with

4
densely-staining granules of 0.1-0.4 ftm diameter (Metcalfe
et al., 1984), that display a crystalline structure
appearing as whorls, scrolls, and lattices (Caulfield et
al., 1980).
IaE Receptors and Deoranulation
The biological activities associated with mast cells
are the result of the effects of mediators that are released
into the extracellular milieu upon mast cell activation.
The complex process of mast cell activation culminates in
the exocytosis of the cytoplasmic granule contents,
including histamine and tryptase, as well as the production
and release of newly formed mediators.

Mast cells have on

their surfaces receptors that bind to the Fc portion of
immunoglobulin E (IgE) molecules (Marom and Casale, 1983).
There are 1-5 x 10s receptors/roast cell and about 10% of
these receptors are normally occupied at any given time
(Metcalfe et al., 1981).

Mast cells are most often

activated by crosslinking (or bridging) of two IgE molecules
by antigen, which initiates a cascade of events involving
movement of calcium into the cell, activation of a cell
membrane associated serine esterase, glycolysis, calcium
liberation, microtubule assembly, and sequential exocytosis
of the granules (Kaliner, 1977).

However, mast cells can be

induced to degranulate in response to other stimuli.

As

shown in Figure 1 (Friedman and Kaliner, 1987), a number of

5
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schematic illustration of selected mast cell

secretagogues*

This figure was adopted with modifications

from Friedman and Kaliner (1987).
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physiological stimuli, such as neuropeptides,
anaphylatoxins, and histamine-releasing factors from other
cell types, as well as non-endogenous compounds, such as
chemicals and drugs, can cause mast cell degranulation*
Even physical stimuli, such as heat, cold and pressure, can
invoke a mast cell response.
Morphologically, degranulation proceeds through many
stages including swelling of the granules, decrease in the
amount of stainable matrix material, disappearance of
crystalline gratings and lattices, increased visualization
of scroll patterns, and the appearance of reticular,
particulate, or flocculent constituents (Caulfield et al.,
1980; Dvorak et al., 1985).

The bridging of IgE receptors

on rat mast cells leads to phospholipid methylation which
induces, among other things, Ca+a influx and histamine
release (Ishizaka et al., 1981).

There have been two modes

of release of granule mediators observed: 1) granular
membranes fuse with other granular membranes and with the
cellular membrane, forming large channels through which the
mediators exit the cell (Trotter and Orr, 1973; Trotter and
Orr, 1974; Hashimoto et al., 1966; Kobayasi and
Asboe-Hansen, 1969; Orr, 1977; Behrendt et al., 1978); or,
2) no large channels form, with the speculation that
transient, small pores allow mediators to escape (Galli et
al., 1984; Berlin and Enerback, 1984; Fernandez et al.,
1984).

Degranulation may not result in extrusion of all

granules/granule contents and is not thought to be cytotoxic
(Friedman and Kaliner, 1985; Friedman et al., 1986; Dvorak
et al., 1985).
Mast cell Mediators
Three types of mediators have been identified in mast
cells: 1) those that are preformed and rapidly dissociate
from the cell upon degranulation; 2) those newly generated
upon mast cell activation; and 3) those that are preformed
but do not readily dissociate from the granule.

These

mediators are summarized in Table 1.
Raoidlv Dissociated.Preformed Mediators
Histamine.

Histamine (5[2-aminoethyl]-imidazole) is

stored in the granules of human mast cells (5 ;ig/10* cells)
in association with heparin proteoglycan, and in human
basophils (l /xg/106 cells) in association with chondroitin-4
sulfates, comprising 5-10% of the human mast cell granule by
weight (White et al., 1987; Wasserman, 1983).

Histamine

diffuses through the tissues rapidly after release and is
detectable in the bloodstream within minutes of mast cell
activation (White et al., 1987).

Histamine exerts its

effects through binding to two types of cell surface
receptors, H, and H2.

Binding of histamine to H, receptors

can cause a variety of effects including smooth muscle
contraction, increased vascular permeability, an increase in

8

Table l. Mast Cell Mediators***
Rapidlv_Dissociated Preformed Mediators
Histamine
Eosinophil chemotactic factor
Neutrophil chemotactic factor
Exoglycosidases (0-hexosaminidase, 0-glucuronidase, 0-Dgalactosidase*)
Arylsulfatase A
Kininogenase"
Serotonin*
Newlv Generated Mediators
SRS-A: Leukotrienes c, D, and E
Prostaglandins and thromboxanes
HETEs
HPETEs
Platelet activating factor
Prostaglandin generating factor
Membrane-bound Preformed Mediators
Heparin
Neutral proteases: Tryptase and Chymase
Arylsulfatase B
Inflammatory factors*
Peroxide*
Superoxide dismutase*
Demonstrated in nonhuman mast cells.

** Kininogenase has

been determined to be tryptase (Proud et al., 1988; Walls et
al., 1992).

*" Compiled from Marom and Casale,

Friedman and Kaliner, 1987.

1983,

and

9
cGMP, prostaglandin generation, pruritus, pulmonary
vasoconstriction, tachycardia, increased nasal mucus
production and activation of airway vagal afferent nerves
(White et al., 1987; Wasserman, 1983).

Binding of histamine

to Ha receptors is responsible for an additional group of
effects including an increase in vascular permeability,
gastric acid secretion, airway mucus production, and cAMP;
stimulation of suppressor T-cells; inhibition of skin and
basophil histamine release and neutrophil chemotaxis and
enzyme release; and bronchodilatation and esophageal
contraction (White et al., 1987; Wasserman, 1983).

Human

diseases associated with histamine release and binding
include asthma, anaphylaxis, urticaria and rhinitis
(Wasserman, 1983).
chemotactic Factors.

Eosinophil chemotactic factors

(ECF), both high and low molecular weight, serve to attract
eosinophils and increase eosinophil receptors for complement
C4 and C3b.

Neutrophil chemotactic factors (NCF) attract

neutrophils and then deactivate them to further chemotactic
activation by other cells (Wasserman, 1983).

There are

several other less well characterized chemotactic factors in
mast cells that affect the migration of T and B lymphocytes
and basophils (Wasserman, 1983).
Acid hydrolases.

Acid hydrolases are located primarily

in lysosomes and function in degradation.

Beta-

10
hexosaminidase removes terminal glucosamine residues from
carbohydrates; fi-glucuronidase removes terminal Bglucuronate residues; and arylsulfatases hydrolyze aromatic
sulfate esters (Wasserman, 1983).
Newly Generated Mediators
Mediators derived from arachidonic acid include slowreacting substances of anaphylaxis (SRS-A), prostaglandins
(PGs), monohydroxyeicosatetraenoic acids (HETEs),
hydroperoxyeicosatetraenoic acids (HPETEs), thromboxanes
(TXs), and platelet activating factor (PAF).
Prostaglandins and Thromboxanes.

PGs and TXs are

derived from arachidonic acid via the cyclooxygenase
pathway.

Chemically, they are

c-20

polyunsaturated hydroxy-

acids with a cyclopentane or oxane ring and they function to
increase cAMP and cGMP, attract eosinophils and neutrophils,
and aggregate platelets.
SRS-A. HETE. HPETE and PAF.

SRS-A, HETE and HPETE are

derived from arachidonic acid via the lipoxygenase pathway
and PAF is an ether analog of phosphatidyl choline.

SRS-A

is made up of the leukotrienes (LT) C, D, and E (6-sulfidoether linked conjugated trienes).

The LTs affect mucus

secretion, while the HETEs and HPETEs affect mediator
release, increase vascular permeability and vasodilatation,
inhibit T cell secretion of lymphokines, and inhibit
lymphokine transformation and lymphocyte-mediated

cytotoxicity (Marom and Casale, 1983).

PAF is the most

potent platelet-aggregating compound known and can cause a
wide variety of other effects such as augmenting neutrophil
migration, enzyme release and oxidative metabolism
(Wasserman, 1983).
Membrane-bound Preformed Mediators
The third type of mediators are not readily dissociated
from the granule membrane following degranulation and may
reguire high ionic strength for separation.

These include

heparin, arylsulfatase B and the neutral proteases
carboxypeptidase, chymase and tryptase.
Heparin.

Heparin is a proteoglycan with highly

sulfated glycosaminoglycan side chains that give it a high
negative charge density (Wasserman, 1983).

Human lung and

skin mast cells contain about 5 pg of heparin (MW 60 kDa)
per 106 cells (Metcalfe et al., 1979; Metcalfe et al., 1980;
Wasserman, 1983).

Some of the activities attributed to

human heparin include binding histamine, inhibiting
complement activation, acting as an anticoagulant, binding
platelet factor 4 and binding and stabilizing the activity
of tryptase (Wasserman and Austen, 1977; Schwartz et al.,
1981b; Smith et al., 1984; Wasserman, 1983).

Rat serosal

mast cells contain about 25 fig of heparin proteoglycan (MW
750 kOa) per 10fi cells, which can bind histamine and inhibit
complement activity (Yurt et al., 1977; Weiler et al..
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1978).
Arvlsulfatase B .

Arylsulfatase B is a glycoprotein

that hydrolyzes aromatic sulfate esters and is present in
rat mast cells and human pulmonary mast cells (Schechter et
al., 1983).
Carboxypeptidase.

Carboxypeptidases isolated from

mouse (Serafin et al., 1987), rat (Everitt and Neurath,
1980), and human (Goldstein et al., 1987; Goldstein et al,
1989) mast cells are zinc-dependent metalloexopeptidases
(Reynolds et al., 1989).

There are two classes of mast cell

carboxypeptidases (MC-CP), designated carboxypeptidase A
(MC-CPA) and carboxypeptidase B (MC-CPB), that exhibit a
substrate specificity for carboxy-terminal
aliphatic/aromatic amino acids and basic amino acids,
respectively (Reynolds et al., 1989).

An MC-CPA has been

isolated from a subset of human mast cells that contain both
of the other mast cell neutral proteases, chymase and
tryptase (Irani et al., 1991).

The mature protein contains

308 amino acids, has a MW of 36.1 kDa, carries a positive
charge of 16 at neutral pH, and functions to remove carboxyterminal Phe and Leu residues from substrates (Reynolds et
al., 1989; Irani et al., 1991).
chvmase.

chymases and tryptases are the two major

neutral serine proteases found in the cytoplasmic granules
of mast cells.

Chymases are chymotrypsin-like enzymes that

cleave target proteins on the carboxyl side of hydrophobic
residues, more specifically Tyr and Phe residues (Craig and
Schwartz, 1989).

They have been isolated from several

species including rodent (Woodbury and Neurath, 1980), sheep
(Huntley et al., 1986), dog (Caughey et al., 1988a) and
human (Schechter et al., 1983).

The enzyme is a monomer of

30 kDa and, like tryptase, is stored in its active form in
the secretory granules, probably bound to heparin (Schechter
et al., 1983; Johnson, et al., 1986; Wintroub et al., 1986;
Sayama et al., 1987).

Unlike tryptase, however, chymase is

inhibited by the plasma proteinase inhibitors alpha-lproteinase inhibitor (a,-PI) and alpha-l-antichymotrypsin
(at-AC)

(Schechter et al., 1989).

Human mast cell chymase

is much more abundant in skin mast cells than in lung mast
cells (Schechter et al., 1983; Schechter et al., 1986).
Human skin chymase is similar to RMCP I (rat chymase) and
dog skin chymase in its activity on synthetic substrates
(Powers et al., 1985).

Chymases have been observed to

convert angiotensin I to angiotensin II (a vasoconstrictor)
in vitro and to inactivate bradykinin and kallidin, two
vasodilators, suggesting a role in initiating or
perpetuating vasoconstriction (Reilly et al., 1982; Reilly
et al., 1985; Wintroub et al., 1984).

Chymase also cleaves

VIP (a bronchodilator), substance P (a potent
bronchoconstrictor and mast cell activator), and calcitonin
gene-related peptide (CGRP) (a potent vasodilator and

bronchoconstrictor)

(Brain et al., 1985; Palmer et al.,

1987; Franconi et al., 1989), further indicating a role in
the control of vasoactive peptides (Brain and Williams,
1988; Caughey et al., 1988b).

Data has also been produced

indicating that chymase is a very potent secretagogue for
airway serous cells (Sommerhoff et al., 1989), supporting a
role for chymase in airway hypersecretion.
Tryptase.

Tryptases have been isolated from a number

of species, including human (Schwartz et al., 1981a; Smith
et al., 1984; Cromlish et al., 1987; Harvima et al., 1988b),
dog (Caughey et al., 1987; Schechter et al., 1988), rat
(Kido et al., 1985a) and bovine (Fiorucci et al., 1992).
Although tryptases in general are 40% identical to trypsin
in amino acid sequence, they differ from trypsin and each
other in several ways.

Unlike trypsin, tryptases are not

inhibited by plasma proteinase inhibitors, such as a,-PI and
alpha-2-macroglobulin (a3M ) , or other trypsin inhibitors,
like bovine pancreatic trypsin inhibitor (BPTI), soybean
trypsin inhibitor (SBTI) and lima bean trypsin inhibitor
(LBTI)

(Schwartz et al., 1981b; Smith et al,, 1984; Cromlish

et al., 1987).

Whereas trypsin cleaves proteins such as

casein and albumin, tryptases are not active on most
proteins.

Also unlike trypsin, human tryptases, both lung

(Schwartz et al., 1981a; Smith et al., 1984) and skin
(Harvima et al., 1988a), have been reported to exist as

te trainers, bind heparin, and show reduced activity with
increasing NaCl concentrations.

Dog tryptase (Caughey et

al., 1987; Schechter et al., 1986), rat tryptase (Kido et
al., 1985a; Braganza and Simmons, 1991), and bovine tryptase
(Fiorucci et al., 1992) displayed similar, although not
identical, characteristics.

Dog tryptase was inhibited by

BPTI; rat tryptase did not bind heparin and was inhibited by
several of the low molecular weight trypsin inhibitors,
specifically o,-PI, SBTI, BPTI, and trypstatin, an
endogenous inhibitor co-localized in rat mast cell granules
(Kido et al., 1988); and bovine tryptase formed oligomers of
360 kDa (subunit sizes of 39 and 41 kDa) and was inhibited
by BPTI, which is actually made in mast cells (Fritz et al.,
1979) .
While tryptase is a poor protease in that there are
very few known natural substrates, there are several
molecules that are known to be cleaved by tryptase.

Of

particular note are vasoactive intestinal peptide (VIP)
(Caughey et al., 1988b; Tam and Caughey, 1990), and high
molecular weight kininogen (HMWK) (Maier et al., 1983).
HMWK is a plasma protein that participates in
coagulation by contributing to the activation of Factor XII
at the beginning of the intrinsic pathway (Movat, 1979).
Cleavage of HMWK by kallikrein releases bradykinin, a
nonapeptide, causing pain, increased vascular permeability,
and bronchoconstriction (Webster, 1970).

Human lung
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tryptase destroyed the procoagulation function of HMWK,
which supports a possible role for tryptase in
anticoagulation, but did not release bradykinin (Maier et
al., 1983).

While it was likely that tryptase inactivated

the procoagulant function of HMWK via cleavage in the Cterminal region, the exact cleavage site was not determined.
VIP is a 28 amino acid neuropeptide that acts as a
potent relaxant of human bronchial and vascular smooth
muscle (Barnes et al., 1984; Morice et al., 1984).

Mast

cells in the lung are in close proximity to nerves
controlling bronchial muscle tone (Stead et al., 1987),
which led Tam and Caughey (1990) to examine the effect of
human lung tryptase on VIP.

They found that tryptase

degrades VIP by cleaving it in several positions, possibly
resulting in a local deficiency of VIP's bronchial relaxant
activity, which may be a contributing factor to asthma-like
symptoms (Said, 1984).
Complement C3, another reported tryptase substrate, is
cleaved to produce the anaphylatoxin C3a, which causes
smooth muscle contraction and increased vascular
permeability (Schwartz et al., 1983).

Fibrinogen, which in

vivo is a substrate for thrombin and a precursor to fibrin
in the blood coagulation cascade, lost all clotting ability
after being cleaved by tryptase in vitro (Schwartz et al.,
1985).

These data suggest possible tryptase involvement in

anticoagulation, the immediate hypersensitivity response,
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and bronchial smooth muscle contraction in asthma-like
conditions.
Other substrates cleaved by tryptases include proatrial natriuretic factor (pro-ANF)

(imada et al., 1987 and

1988; Seidah et al., 1986; Proctor et al., 1991; Wypij and
Harris, 1988) to produce ANF, a potent diuretic, natriuretic
and hypotensive (DeBold, 1985); peptide histidine-methionine
(PHM), a potent bronchodilating peptide, and CGRP, a potent
vasodilator and bronchoconstrictor (Tam and Caughey, 1990);
kinetensin, a peptide isolated from pepsin-treated human
plasma that shares homology with neurotensin and angiotensin
(Mogard et al., 1986; Goldstein et al., 1991); prothrombin
to thrombin (Kido et al., 1985b; Dietze et al., 1990); and
synovial procollagenase and/or pro-stromelysin (Gruber et
al., 1988; Gruber et al., 1989) to produce stromelysin and
collagenase, which degrade proteoglycans, fibronectin,
laminin, type IV and type IX collagen, and gelatin (Sellers
et al., 1978; Harris et al., 1984; Okada et al., 1986).
Johnson and Cawston (1985) reported that tryptase was not a
direct activator of procollagenase.

Gruber et al. (1988)

later reported that tryptase was an activator of
procollagenase, but subsequently (Gruber et al., 1989)
reported that tryptase only activated prostroraelysin which
then activated procollagenase, confirming the original data
of Johnson and Cawston.

These data suggest that tryptase

could be involved in the control of fluid volume and blood
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pressure control (Wypij and Harris, 1988), bronchial tone
(Taro and Caughey, 1990) and contribute to matrix degradation
in rheumatoid arthritis (Gruber et al., 1989).

There is a

conflicting report about the ability of human tryptase to
cleave prothrombin (Harvima et al., 1989), leaving doubt as
to its potential procoagulant activity.

Most of these

substrate studies were performed in vitro and ,therefore,
their in vivo significance is unclear.
To investigate the underlying structural features of
tryptase responsible for the tendency to form
tetramers/oligomers and for the seeming unavailability of
the active site for interaction with protein substrates and
inhibitors, Johnson and Barton (1992) performed computer
molecular modelling studies based on the structure of bovine
trypsin.

Their data showed two large insertions on either

side of the substrate binding pocket that may limit access
of many substrates and inhibitors to the active site.
Additionally, two hydrophobic patches unique to the
tryptases were apparent on the models and may contribute to
tetramer formation and/or interaction with other hydrophobic
molecules such as membranes.
in experimental studies previously performed, the human
lung roast cell tryptase preparations used may have contained
one or more isozymic forms.

Two different tryptase cDNAs

have been cloned from a human lung tissue library (Miller et
al.,

1989; Miller et al., 1990) and three from a human Bkin
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cDNA library (Vanderslice et al., 1990), one of which was
identical to one of the lung cDNAs.

A dog tryptase has been

cloned from dog mastocytoma cells (Vanderslice et al., 1989)
and two mouse tryptases have been cloned from a mouse mast
cell line (chu 1990; Reynolds et al., 1991; McNeil et al.,
1992).

The amino acid sequences derived from these cDNAs

are shown aligned with trypsin and chymotrypsin in Figure 2.
The coding regions of all of the tryptases are 244 or 245
amino acids in length with one or two putative N-linked
glycosylation sites (Asn-Xaa-Thr/Ser).

The human tryptases

show >90% sequence identity to each other and 73-78%
identity to dog tryptase whereas the two mouse tryptases
share only 70% identity to each other.

A high degree of

homology between all the tryptases in an 11 amino acid
propeptide is also observed.

The propeptide is unusual in

that it ends in a Gly residue, which is unique among the
serine proteases and suggests a novel mode of activation
(Vanderslice, 1989).

All of the tryptases have an Asp

residue in the proposed base of the substrate binding
pocket, conferring the preference of tryptase for substrates
having Lys or Arg at the PI position.

Multiple cDNAs

isolated from humans and evidence of multiple tryptase genes
(Vanderslice, 1990) suggest the existence of multiple active
forms of the enzyme.
Mast Cell Heterogeneity
It should be noted that not all mast cells produce
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Figure 2 . Sequence alignment used for modelling the mast cell tryptases showing the sequences o f the tryptases in comparison to those o f trypsin
and chymotrypsin. HST-1, human skin tryptase 1; HST-2/HLT-0, human skin tryptase 2/human lung tryptase beta; HST3, human skin tryptase
3, HLT-ct, human lung tryptase alpha; M M C T-l, mouse mast cell tryptase 1; MMCT-2, mouse mast cell tryptase 2; DMCT, dog mast cell
tryptase; trypsin, bovine trypsin, chymotrypsin, bovine chymotrypsin. Numbering follows M M CT-l, while asterisks * above and below the
alignment highlight the active site His, Asp and Ser residues. Exclamation marks ‘I’ highlight the Asp in the S ’ binding pocket. Asn-linked
gtycosylation sites are shown in lower case, italicized bold print. Sequence identity percentages relative to M MCT-l and MMCT-2 are at the
ends o f the sequences.

equivalent amounts of the various mediators, even within the
same individual.

For example, mast cells from human lung

released a much higher amount of histamine and leukotrienes
D4 and E4 than those from human foreskin (Church et al.,
1989).

Varying amounts of the neutral proteases tryptase

and chymase have led to a proposed system of nomenclature
for human mast cells based on the presence or absence of
these two enzymes.

Hast cells containing tryptase but no

chymase have been labeled T mast cells (MCf), while mast
cells containing both tryptase and chymase have been labeled
TC mast cells (HC^)

(Irani et al., 1986).

Ninety percent

of the total number of mast cells found in human pulmonary
tissue and 98% in intestinal mucosa were the T type, whereas
the TC type accounted for 88% of mast cells in human skin
and 87% in intestinal submucosa (Irani et al., 1986).

It

has been determined that T mast cells contain approximately
10.8 pg of tryptase per cell while TC mast cells contain
approximately 35 pg of tryptase and 4.5 pg of chymase per
cell (Schwartz et al., 1987c).
Rat mast cells have been categorized as either mucosal
or connective tissue type based primarily on location and
the type of chymotrypsin-like enzyme present.

Connective

tissue type mast cells contain a chymase called rat mast
cell protease I (RMCP I) (Yurt and Austen, 1977; Seppa and
Jarvinen, 1978; Woodbury et al., 197Ba) and mucosal type
mast cells contain a chymase called RHCP II (Woodbury et
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al., 1978b).

The physiological significance of mast cell

heterogeneity between tissues is not clearly understood.
Pathogenesis of Mast, cells
Mast cells are thought to participate in normal
homeostasis by contributing to: resistance to parasitic
infestation {Miller and Jarrett, 1971; Haig et al., 1984;
Capron et al., 1978), wound healing (Matsuda and Kitamura,
1981), angiogenesis (Azezthan et al., 1980; Kessler et al.,
1976), and tumor immunity (Henderson et al., 1981; Farram
and Nelson, 1980).

They have also been implicated in a

number of pathological conditions, including anaphylaxis
(Austen, 1974), asthma (Crisp et al., 1984; Godfrey et al.,
1984), inflammatory bowel disease (Dvorak et al., 1980;
Barrett and Metcalfe, 1984), and rheumatoid arthritis
(Wasserman, 1984).

The symptoms in these disease states

range from acute and life-threatening to chronic and
debilitating.

It is apparent from the above information

that the basic biochemical functions of mast cells and their
mediators in health and disease are varied and complex, and
an understanding of them is crucial in the guest to maintain
or restore health.
Project Objectives and Overview
In spite of the knowledge of multiple cDNAs and genes
for human tryptase, there is no information concerning
possible functional differences between the various forms of

tryptase, neither has it been possible to correlate
different electrophoretic forms with cDNA sequences.

This

project was designed to fill these knowledge gaps by
isolating human tryptase isozymes, which could then be
compared with regard to structure and function.
Two forms of the human lung tryptase, differing in
molecular weight, were partially separated by
chromatographic techniques and were shown in this laboratory
to be independently active (smith et al., 1984).

Starting

with human lung tissue, two forms of active tryptase have
been isolated, which are designated high-HLT (high molecular
weight human lung tryptase) and low-HLT (low molecular
weight human lung tryptase).

These two isozymes have been

examined, and in some cases compared, with respect to their
structural and functional characteristics in an attempt to
confirm the existence of two independently active tryptases
in human lung, to partially define those differences, and to
determine their relationship to the previously discussed
cDNAs cloned from human lung mast cells.

CHAPTER 2
MATERIALS AND METHODS

Materials
Frozen human lung tissue was procured through the
National Disease Research Interchange.

Cellulose phosphate

(fibrous form), cetylpyridinium chloride, porcine heparin
(ammonium salt, average MW = 10,000), DTNB, Cbz-Lys-SBzl,
Brilliant Blue G Colloidal Concentrate, fish gelatin,
trichoroacetic acid, TFA, and Amino Acid Standard solution
(#A97B1) were purchased from Sigma Chemical Company.

MES,

NaCl, NaNj, glycerol, HEPES, Brij 35, DMSO, HN03, enzyme
grade sodium acetate trihydrate, HPLC grade acetonitrile
were products of Fisher Scientific.

Enzyme grade ammonium

sulfate was purchased from ICN Biomedicals.

Spectra/Por

standard dialysis tubing (4.5 cm; 12,000-14,000 MWC0) was a
product of Spectrum Medical Industries, Inc.

Absolute (200

proof) ethanol was a product of AAPER Alcohol & Chemical Co.
HPLC grade triethylamine was purchased from Pierce Chemical
Co.

Copper Stain & Destain Kit was purchased from Bio-Rad

Laboratories.

Toyopearl Butyl 650-M hydrophobic interaction

chromatography column material was purchased from TosoHaas,
Sephacryl S200-HR gel filtration column material was
purchased from Pharmacia.
Inc.

VIP was purchased from Bachem,

Recombinant N-Glycanase was purchased from Genzyme.

glass-lined, 300A pore, Nucleosil C„, HPLC column (4mm x
24

A
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250mm) was purchased from SGE.

Pico-tag C„ column and

Immobilon-P PVDF membrane were purchased from Millipore and
PVDF-Plus Transfer Membrane was obtained from MSI,
NH^acetate, purchased from Mallinckrodt, was kindly provided
by Dr. M.-L. Ernst-Fonberg.

SLPI was kindly provided by Dr.

R. Thompson (Synergen, Boulder, CO).

Arg15Glu51aprotinin was

graciously provided by Dr. H. Fritz (Univ. of Munich,
Munich, Germany).
(Univ. of

s.

ASTI was the kind gift of Dr. R. Peanasky

Dakota, Vermillion, SD).

Ial was the kind gift

of Dr. J. Enghild (Duke Univ., Durham, NC).

APPI was kindly

provided by Dr. T. Hynes (Genentech, Inc., San Francisco,
CA).

Ecotin was the kind gift of Dr. M. McGrath (Univ. of

California at San Francisco, SF, CA).

CMTI-III was kindly

provided by Dr. c. McWherter (Monsanto, St. Louis, MO).
Protein G Gold Immun-blot Assay Kit, purchased from Bio-Rad,
was kindly provided by Dr. J. Suttles.

Monoclonal

antibodies to the light chain of HMWK were graciously
furnished by Dr. A. Schmeier (University of Michigan, Ann
Arbor).

Laminin, plasminogen-free fibrinogen, and

fibronectin were the kind gifts of Dr. S. Stack (Duke
University, Durham,NC).

Fresh frozen human blood plasma was

obtained from the American Red Cross.

All other reagents

were ACS grade unless otherwise specified.
Trvotase Activity Assay
Enzyme activity was monitored using the substrate Cbz-

26
Lys-SBzl, which when hydrolyzed produces a free thiol that
reacts with DTNB to produce a yellow color.

The chemical

reaction involved is shown helow:

Tryptase

C b z-L y s-S B zl— >

C b z-L y s-C O , + HSBz]
Yellow

C o lo r

One unit of activity was defined as the amount of enzyme
needed to produce an increase in absorbance at 410 nm (A4I0)
of 1.0/minute.

Specific activity was defined as the

increase in A^/minute/ml divided by the A3I0.

An appropriate

amount of enzyme was added to 0.1 M HEPES, 10 pK heparin
(100 /ig/ml), 10% glycerol, 0.05% Brij 35, 0.02% NaNJ( pH 7.5
(assay buffer) containing 1 mM DTNB for a total volume of
980 /il.

Assays were started by adding 20 nl of 20 mM Cbz-

Lys-SBzl in DMSO for a final volume of 1 ml (final substrate
concentration equaled 0.4 mM) and the change in A410/minute
was monitored for 3 minutes at room temperature in a Beckman
DU-30 spectrophotometer using the kinetics data program on
the Beckman Kinetics cartridge,

chromatography fractions

were assayed using a microtiter plate reader and 96-well
microtiter plates with the assay incubation mixture reduced
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proportionately to 200/il.
Tryptase Purification
Frozen human lung tissue (500 g) was cut into small
pieces and disrupted in a Waring blender with 500 ml of cold
distilled HjO for 10-15 seconds.

The homogenate was

centrifuged at 25,400 x g for 20 min. in a Beckman J-21C
centrifuge at 5°C and the supernatant was discarded.

The

blending and centrifuging process was repeated using cold 20
mM MES with 0.15 M NaCl and 0.02% NaN3 at pH 6.1 in place of
dH20 until supernatant fractions were visibly free of
hemoglobin.

Tryptase activity was extracted from the tissue

by repeating the blending and centrifuging process four
times using 500 ml of cold 20 mM MES 2 M NaCl 0.02% NaN3 pH
6.1 each time*

The viscosity of the crude extract was

reduced by removing the lipid present; this involved adding
an equal volume of 2% cetylpyridinium chloride in lOmM MES
0.02% NaNj pH 6.1 and incubating at room temperature for 30
minutes followed by centrifugation at 25,400 x g (5°C) for
60 minutes.

The extract was then made 2 M in (NH4)2S04,

centrifuged as above, and filtered through glass wool.

This

filtrate was mixed with 50 ml of Toyopearl Butyl 650-M
column material equilibrated with 10 mM MES, 0.5 M NaCl, 2 M
(NH4)2S04, 20% glycerol, 0.02% NaN3, pH 6.1 and incubated at
room temperature for 45 minutes.

This mixture was

centrifuged at 5860 x g (5°C) and the supernatant containing
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unbound proteins was decanted and tested for activity.

The

column material with bound tryptase was collected by
centrifugation/ the slurry was poured into a chromatography
tube (2.2 x 12 cm) and washed extensively with equilibration
buffer.

All of the tryptase activity bound to the column

material and was subsequently eluted with a 250 ml linear
gradient of decreasing ionic strength from 2.0 to 0.0 H
(NH4)3S04, collecting 2 ml fractions at one minute intervals.
The active fractions were pooled/ made 0.05% in Brij 35, and
dialyzed against 4 liters of 10 mM MES, 0.3 M NaCl, 0.02%
NaN3, pH 6.1 for 3 hours at 4°C, followed by dialysis
against 4 liters of the same buffer containing 20% glycerol
for 3 hours.

This pool was then loaded onto a 20 ml

cellulose phosphate column equilibrated with the last
dialysis buffer.

After washing with equilibration buffer,

one of two elution profiles was used.

Either high-HLT was

eluted first with 10 jxM heparin in equilibration buffer,
followed by elution of low-HLT with 1 M NaCl in
equilibration buffer, or a gradient of 0.3 M to 1.5 M NaCl
and 0 to 50 /*M heparin in equilibration buffer was used to
elute both isozymes, with the high-HLT eluting first.

The

total gradient volume was 150 ml and 1 ml fractions were
collected at 1 ml/minute for both elution profiles.

The

overall recovery of activity was usually about 25% with the
high M, fraction representing approximately 85% of the total
and the low M, form accounted for 15% of the activity on
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Cbz-Lys-SB2l.

The active fractions from each peak were

pooled and analyzed by SDS-PAGE.
Electrophoresis
SDS-PAGE analysis of proteins or cleavage products was
carried out under reducing conditions on 1.5 nun thick 6%, 8%
or 10% polyacrylamide gels as described by Bury (1981).
Proteins were stacked at 15 mA and the current was increased
to 20 mA after the dye front entered the separating gel.
The gels were placed in MetOH/acetic acid/H20 (40%/7%/53%
v/v) to fix the proteins in the gels, stained with colloidal
Coomassie Brilliant Blue and destained with MetOH/acetic
acid/H20 (25%/l0%/65% v/v) for 30 seconds followed by
Met0H/H20 (25%/75% v/v) until the background stain
disappeared.
Electroelution of Proteins from SDS-PAGE
High-HLT and low-HLT were electroeluted from SDS-PAGE
gel slices for the purpose of performing a Western blot.
High-HLT and low-HLT (240 fig of each) were TCA precipitated
and electrophoresed as described above.

High-HLT was

electrophoresed on two gels, loading 20 fig per lane in 12
total lanes.

After electrophoresis, the gels were stained

with copper stain, which stains the gel a light blue while
leaving the protein bands unstained, and the bands
containing high-HLT were cut out of the gels, destained, and
loaded in an IBI, Model UEA, electroelution apparatus.

The
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protein was electroeluted from the gel slices into 7.5 M
NH^acetate at 50 V for 2% hours.

The Nl^acetate solution

containing the high-HLT was removed from the apparatus,
separated into 6 microcentrifuge tubes and the protein was
precipitated with TCA as described previously.
procedure was repeated with low-HLT.

The

It was estimated that

each tube contained approximately 20 pg of protein.
Active Site Titration
Active site titrations were performed on each tryptase
isozyme using the titrant 4-methylumbelliferyl pguanidinobenzoate hydrochloride (MUGB), which reacts with
the active site serine of trypsin-like enzymes (Jameson et
al., 1973).

The excitation and emission wavelengths were

365 nm and 445 nm, respectively, and known concentrations of
the fluorescent product, 7-amino-4-methyl coumarin (AMC),
were used as standards.

A stock solution of 0.1 H AMC in

0MS0 was diluted 1:100 with 0.1 M HEPES, 10 pH heparin, 10%
glycerol, 0.05% Brij, 0.02 NaN3, pH 7.5 to produce a 1
nmol/ml solution.

The fluorimeter was calibrated to zero

against 500 pmol of substrate in l ml of assay buffer.

A

solution containing 100 pmol/ml of AMC in assay buffer was
used to set the fluorimeter manually to a value of 100.
Standards of 10, 20, 40, 60, and 80 pmol in a final volume
of 1 ml were read and the fluorescence values were plotted
against the molar values to produce a standard line.

Five
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hundred pmol of substrate and a range of 20-200 pmol of
enzyme was used per assay in a final volume of l ml.
Dealvcosvlation of Tryptase Isozymes
Two aliquots of 20 fig each of high-HLT and low-HLT were
TCA precipitated in 1.5 ml microcentrifuge tubes by adding
TCA to each sample for a final concentration of 20% and
incubating the samples on ice for 1 hour, followed by
centrifugation and washing of the precipitates twice with
700 Mi of cold 10% TCA and twice with 700 Mi of cold acetone
and drying at room temperature.

The precipitated protein

was resolubilized by adding 10 Mi of 20 mM Tris pH 7.5
containing 0.5% SDS, 50 mM /3-ME and 0.02% NaNj and heating
at 95°C for 5 minutes.

To one tube of each isozyme, 5 Mi of

7.5% NP-40 was added along with 1.2 Mi of N-Glycanase enzyme
(9.1 M9/roi) and 13.8 Mi of dH20 was added to all four tubes.
The samples were incubated at 43°c for 21 hours followed by
the addition of 25 Mi SDS ammediol sample buffer containing
1% 0-ME and electrophoresis as described previously using 25
Ml of each sample, a 10% 1.5 mm gel, and colloidal Coomassie
Brilliant blue stain.
High-HLT was also deglycosylated without denaturation
and reduction to determine if the activity was reduced as a
result of deglycosylation.

One hundred Mi (4.8 fig) of high-

HLT was incubated with 2 Mi of N-Glycanase at 43°C for 21
hours.

A control of 100 Mi of high-HLT with no N-Glycanase

was also incubated as above.

After cooling, the control,

the treated sample, and the high-HLT pool before incubation
at 43°c were assayed using Cbz-Lys-SBzl as the substrate.
Fifty /Jl of the control and the treated sample were then TCA
precipitated, electrophoresed on a 10% 1.0 mm SDS gel and
stained with silver stain.
Western Blot Analysis
Proteins were electroblotted onto either Immobilon-P or
PVDF-Plus membrane.

Electrophoresis of proteins to be

transferred was carried out as above except that the gel
thickness was reduced to 1.0 mm.

The gels were subsequently

equilibrated in 48 mM Tris, 39 mM glycine, 20% MetOH pH 9.2
and the proteins were transferred to the membrane at 15 V
constant voltage for 40 minutes in a Bio-Rad Transblot SD
Semi-Dry Transfer Cell.

The membranes were blocked with 3%

fish gelatin or BSA for one hour and exposed to primary
antibody for 15 hours with gentle shaking at room
temperature.

The primary antibody solution for analysis of

high- HLT or low-HLT consisted of a 1:2000 (v/v) dilution of
rabbit anti-HLT antibody in TBS (20 mM Tris 500 mM NaCl
0.02% NaN3 pH 7.5).

The secondary antibody solution

consisted of a 1:2000 (v/v) of goat anti-rabbit IgG antibody
conjugated with alkaline-phosphatase in TBS.

The reactive

proteins were visualized by development of the alkalinephosphatase with NBT/BCIP,

The primary antibody solution
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for analysis

ofthe HMWK cleavage products consisted of a

1:1000 (v/v)

dilution of a monoclonal antibody to the

carboxy terminal region of HMWK in TTBS (20mM Tris 500mM
NaCl 0.05% Tween-20 0.02% NaN} pH 7.5) with 1% gelatin.

The

membranes were then exposed to Protein 6 Gold solution (a
1:25 dilution of the stock solution provided in 20 mM
citrate pH 5.5 containing 500 mM NaCl, 0.1% BSA, 0.05%
Tween-20, 0.02% NaN3 and 0.4% fish gelatin) to detect bound
IgG and further developed using Bio-Rad's Bilver enhancement
procedure.

This involved incubating the membrane in citrate

buffer (0.2 M citrate, 75 mM sodium citrate pH 3.7) for five
minutes followed by incubation for 5-15 minutes in
enhancement solution (a mixture of 0.11 g of silver lactate
dissolved in

10 ml of dH20 with 0.85 g of hydroguinone

dissolved in

90 ml of citrate buffer)

in the dark.

The

enhancement reaction was stopped by rinsing the membrane
with dH20 and the silver was fixed on the membrane by
rinsing with a 1:10 dilution of the fixing solution in dH20
for five minutes.
Gel Filtration
Sephacryl S200-HR column material (155 ml) was washed
with dH20, equilibrated with 10 mM MES, 1.5 M NaCl, 20%
glycerol, 0.02% NaNj pH 6.1, and poured into a 1.5 x 88 cm
glass chromatography tube.

The void volume (V0) was

determined to be 60 ml by applying 500 nl of a solution of

blue dextran (MW = 2000 kDa) with an A2I0 of 0.5 to the
column, eluting at 0.5 ml/minute.

To calibrate the column

further, additional standards solutions were made up as
follows:

IgG (3 mg/ml, A2J0 = 2.2, MW - 150 kDa); BSA (4

mg/ml, AjS0 = 5.0, MW = 67 kDa); and chymotrypsinogen A (4
mg/ml, Aj(0 = 15, MW <= 25 kDa).

IgG (500 jil) was loaded on

the column and eluted with a flow rate of 0.5 ml/minute.
Fifty ml of buffer was collected into a graduated cylinder
before collecting 70 fractions.

The A210 of each fraction

was read and plotted on the Y-axis vs. the fraction number
on the x-axis.

The chromatography and plotting described

above was repeated using BSA as the standard and again using
chymotrypsinogen A (except that 250 /il was loaded).

Then

new solutions of the three standards were prepared with
concentrations of 8 mg/ml, 250 /il of each standard was mixed
and the mixture was chromatographed as above.

A solution of

tryptase containing both high-HLT and low-HLT (A^o = 0.226,
approximate total protein = 1 . 4 5 mg) was concentrated from
18 ml to 1.5 ml in an Amicon pressure cell using a 10,000
MWCO (YM-10) membrane and chromatographed on the
standardized column.

The absorbance of the fractions was

read at 280 nm and a microtiter plate assay of the fractions
was performed as previously described.

The peaks of

activity were pooled separately and analyzed by SDS-PAGE and
Western blotting.
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Inhibitor Assays Using cbz-Lvs-SBzl as the substrate
The inhibitors tested for activity against high-HLT
using Cbz-Lys-SBzl as the substrate were recombinant human
Alzheimer's amyloid precursor protein inhibitor (APPI) ,
human inter-a-trypsin inhibitor (Ial), recombinant bovine
ArglJGlu5Iaprotinin (also known as bovine pancreatic trypsin
inhibitor or Trasylol), recombinant human secretory
leukocyte proteinase inhibitor (SLPI), Ascaris suum trypsin
inhibitor (ASTI), and ecotin (a trypsin inhibitor from E.
coli).

Curcurbita maxima trypsin inhibitor-III (CMTI-III; a

trypsin inhibitor from squash seed) was tested with high-HLT
and low-HLT.
SLPI. Ecotin. and ASTI.

Fifty nl of high-HLT (37

ng/ml; 57.5 pmol) and 575 pmol of inhibitor (a 1:10
enzyme:inhibitor molar ratio) was added to 100 ftl of assay
buffer (0.1 H HEPES pH 7.5 containing 0.05% Brij 35 and
0.02% NaN3) in a 1 ml cuvette and incubated at room
temperature for 10 minutes, 20 minutes or 60 minutes.
Remaining tryptase activity was assayed using the Cbz-LysSBzl substrate as previously described.

Controls were exact

duplicates of the samples except that no inhibitor was
added.
APPI and Ial.

Assays were performed in 1 ml

spectrophotometric cuvettes at room temperature using a
1:100 enzyme:inhibitor molar ratio.

Inhibitors (APPI, 18.4

Ml = 2.88 nmol = 18.4 pg; or Ial, 170 nl - 2.88nmol = 634

Mg) were added to 200 Ml of assay buffer (0.1 M HEPES pH 7.5
containing 10 pK heparin, 10 % glycerol, 0.05% Brij 35, and
0.02% NaNj) containing 25 pi of high-HLT (28.75 pmol; 0.93
fig) and incubated at room temperature for 3 hours.

A

control of 25 pi of high-HLT in 200 pi of assay buffer was
also incubated as above.

Remaining tryptase activity was

assayed with Cbz-Lys-SBzl substrate as previously described.
This experiment was repeated using 400 m! of assay buffer
and 1.44 nmol of each inhibitor and 14.38 pmol of high-HLT.
Also included were assays using 0.1 M Tris buffer pH 8.0,
8.5, and 8.8.

The incubation and assay conditions were

identical to the ones described above.
ArQlsGluiJ aorotinin.

This procedure was performed

essentially as above using 200 pi of assay buffer (0.1 M
HEPES pH 7.5 containing 10 m** heparin, 10 % glycerol, 0.05%
Brij 35, and 0.02% NaNj), 25 Ml of high-HLT (28.6 pmol; 915
ng), and 18.7 pi of Arg15GluM aprotinin (2.88 nmol; 18.7 pg).
A control was performed using 200 Ml of assay buffer and 25
Ml of high-HLT.

The samples were incubated at room

temperature for 10 minutes, followed by an activity assay
using Cbz-Lys-SBzl as described above.
CMTI-III.
350 Ml

This procedure was performed as above using

the above assay buffer, 140 pmol of CMTI-III (4.6

Ml of a 100 pg/m1 solution; 460 ng) and 3 pmol of active

low-HLT (20 pmol of protein; » a 1:50 molar E:I ratio based
on active sites of low-HLT).

A control was performed using

350 pi of assay buffer and 1.4 pmol of low-HLT.

The samples

were incubated at room temperature for four hours, followed
by an activity assay using Cbz-Lys-SBzl as described above.
This experiment was repeated using 350 pi of HEPES assay
buffer at pH 7.5, or Tris assay buffer at pH's 8.0 or 8.5
per sample.

Low-HLT (20 pmol of protein) and CMTI-III (2

nmol)(a 1:100 molar E:I based on protein concentration or a
1:667 E:l based on active sites of low-HLT) were added to
each sample cuvette and incubated and assayed as above.
Identical assays were also performed using 100 pi of pH 8.0
assay buffer, 20 pmol of low-HLT or 5 pi of high-HLT
(concentration not recorded), and 2 nmol of CMTI-III.
q?M and g,i, Activity Assay
Bovine alpha-2-macroglobulin (a2M) (9.8 mg/ml = 1 3 . 5
nmol/ml) that had been stored at -80°C for two years was
diluted l:l with 0.1 M Tris pH 8.0 (assay buffer).

Porcine

trypsin (100 pi of a 2 nmol/ml solution = 0 . 2 nmol) was used
per reaction.

A 6% solution (w/v) of azocasein in dHzo was

used as the substrate due to the unique mechanism of action
of

ck3M

(refer to Results).

A series of reactions were set

up in 1.5 ml microcentrifuge tubes as follows:
1)

blank = 100 pi azocasein + 900 pi AB (assay buffer)

2)

100 pi trypsin + 800 pi AB
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3)

"

+ 790 #il AB + 10 fil OjM (*0.07 nmol)

4)

»

+ 780 Hi AB + 20 /il

5)

"

+ 770 Ml AB + 30 Ml

6)

"

+ 760 Ml AB + 40 Ml

7)

"

+ 750 Ml AB + 50 fil

8)

••

+ 725 Ml AB + 75 Ml

9)

"

+ 700 Ml AB + 100 Ml

(»o.67 nmol)

The reaction was started by the addition of 100 Ml °f 6%
azocasein to each tube, followed by incubation at room
temperature for 20 minutes.

The reaction was stopped and

the undigested azocasein and other proteins were
precipitated by the addition of 200 Ml of 20% TCA to each
tube.

The samples were centrifuged for 5 minutes and the

absorbance of each supernatant was read at 366 nm.

The

basis of this assay is that uncleaved proteins are more
readily precipitated than small cleavage products.
Therefore, the control (sample 2), containing only trypsin
and azocasein, would theoretically have the largest amount
of protein (cleaved) left in the supernatant after TCA
precipitation and centrifugation and, consequently, would
retain the highest absorbance at 366 nm.

As increasing

amounts of inhibitor were added, the A ^ of the samples
should decrease due to the decreased amount of enzyme
available to digest the azocasein.

Sample 2 (no inhibitor)

was designated as producing 100% activity based on the
absorbance relative to the blank and the absorbances of

39
samples 3 - 9

were used to determine the percent of activity

relative to sample 2.

The percent activity (Y-axis) was

plotted against the pi of a2M (X-axis) to determine the
relative activity of the a2M.
The above assay was repeated using rat alpha-1inhibitor-3 (a,I3) (6.4 mg/ml = 33.7 nmol/ml) as the
inhibitor.

The stock solution was diluted 1:5 with assay

buffer and the amounts used were 10, 20, 30, 40, 50, 75,
100, 150 ftl (»0.Q7 nmol - 1.0 nmol).

The amount of assay

buffer used per reaction was adjusted accordingly to produce
a final reaction volume of l ml.
Inhibitor Assays Using HMWK as the substrate
The inhibitors tested for activity against the tryptase
isozymes using HMWK as the substrate were bovine a2M, rat
a,I3 (the rat equivalent to human a2M), APPI, Ial, ASTI, SLPI
and CMTI-III.
a,M and

HMWK was used as the substrate for these

inhibitory assays of tryptase and trypsin was used as a
control enzyme.

High-HLT (0.88 pmol of tetrameric enzyme,

3.52 pmol of active sites; 2.64 pi of a 46.5 pg/ml solution)
was added to each of three 1.5 ml microcentrifuge tubes
containing 240 pi of assay buffer (0.1 M HEPES pH 7.5
containing 0.05% Brij 35 and 0.02% NaNj).

To one of the

tubes, 2.6 pi (2.6 pg, 3.51 pmol) of a2M was added and to
another tube 2.64 pi (1.34 pg, 3.51 pmol) of a,I3 was added
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(a 1:4 molar ratio of E:1 based on a tetrameric enzyme or a
1:1 based on tryptase active sites) and all three tubes were
incubated at room temperature for 30 minutes.

Trypsin was

added to three additional tubes containing 240 /il of assay
buffer and the same amount of ajM and atI3 as above was added
to two of these tubes and incubated as above.

After 30

minutes, 258 (il (50 ng, 438 pmol; a 1:125 molar ratio of E:S
based on number of active sites of enzyme) of HMWK was added
to each tube and 130 jil ( 25

219 pmol) of HMWK was added

to a seventh tube for a control and all the tubes were
incubated at 37°c for 20 minutes.

The reaction was stopped

by the addition of cold 40% TCA for a final concentration of
20%.

After centrifugation, the precipitates were washed

with cold 10% TCA and acetone and dried.

The samples were

solubilized with 50 /il of Tris-HCl sample buffer containing
5% /J-ME and heated at 95*C for 10 minutes and cooled.
Twenty /il (20 /ig) of each sample were analyzed on a 7% SDSPAGE gel using the ammediol buffer system and the proteins
were visualized with colloidal Coomassie Brilliant Blue
stain.
Arg15GluMaprotlnin.

Trypsin (3.52 pmol) or high-HLT

(3.52 pmol) and inhibitor (352 pmol) were added to each of
seven 1.5 ml microcentrifuge tubes containing 400 /il of
reaction buffer of either pH 7.5 or pH 9.1 (0.1 M HEPES pH
7.5 containing 10 /tM heparin, 10 % glycerol, 0.05% Brij 35,
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0.02% NaN3 or 0.1 M Tris pH 9.1 containing the same
additives) as listed below:
1) pH 7.5 + HMWK
2)

n

+

ii

+

3)

ii

+

it

+

+ inhibitor
(352 pmol)

4)

n

+

ii

+

S)

ti

+

ii

.f

6) pH 9.1 +

ii

4.

+

"

+

7)

ii

The E:I ratio was 1:200
incubating the enzyme and inhibitor at room temperature for
30 minutes, HMWK (20 jug; 176 pmol) was added to each tube
and an additional 60 minute incubation was allowed at room
temperature.

The reactions were stopped by TCA

precipitation and the samples were prepared and
electrophoresed on a 7%, 1.5 mm gel as previously described.
APPI. Ial. ASTI and SLPI.

HMWK (20 /ig; 176 pmol) was

put into each of six 1.5 ml microcentrifuge tubes containing
400 fil of reaction buffer (0.1 M Tris pH 8.5 containing 10
/iM heparin, 10 % glycerol, 0.05% Brij 35 and 0.02% NaN}) .
High-HLT (3.52 pmol; 113 ng) was added to each of five of
the tubes, and 352 pmol of APPI, Ial, ASTI or SLPI were
added to four of the tubes containing the high-HLT (for a
1:100 molar ratio of E:I).

All 6 tubes were incubated at

room temperature for 30 minutes.

HMWK (176 pmol) was then

added to all tubes containing high-HLT (for a 1:50 molar
ratio of E:S) and the samples were incubated at room
temperature for 60 minutes.

The samples were then

precipitated with TCA as previously described and were
analyzed by SDS-PAGE.

A 7% 1.0 mm gel was used and the

samples were visualized using colloidal Coomassie Brilliant
blue stain.
CMTI-III.

Low-HLT (2.22 pmol of protein or 0.33 pmol

of active sites; a 1:100 E:I ratio based on protein
concentration or a 1:667 ratio based on number of active
sites of low-HLT) or high-HLT (2.12 Ml/ concentration not
recorded) was incubated with CMTI-III (222 pmol) in 1.5 ml
microcentrifuge tubes containing 315 Ml of assay buffer (0.1
M HEPES pH 7.5 containing 10 mM heparin, 20% glycerol, 0.05%
Brij 35, 0.02% NaNj) for 4 hours at room temperature.

HMWK

(443 pmol; 50 ng; a 1:200 E:S ratio based on protein
concentration or a 1:1342 E:S ratio based on number of lowHLT active sites) was added to each tube and the mixtures
were incubated for another 30 minutes at room temperature.
Each sample mixture was then divided into 3 tubes containing
146 Ml each and the proteins were precipitated by the
addition of 1314 Ml of Ice cold absolute EtOH to each tube
and storage at -20°c overnight.

A control containing 126 Ml

of assay buffer, 0.89 pmol of low-HLT, and 20 ng of HMWK was
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prepared in the same way and precipitated in a single tube
using 1350 pi of cold EtOH*

The precipitated proteins were

collected by centrifugation, the supernatant was discarded,
and the precipitates were dried at room temperature.

The

samples were solubilized with 10 pi of IX SDS ammediol
sample buffer containing 1% 0-ME, the control with 30 pi of
the same sample buffer and 50 pi of sample buffer were added
to 10 pi of MW standards.
10 minutes and cooled.

All tubes were heated to 95°C for

The samples and standards were

electrophoresed on an 8% 1.5mm SDS-polyacrylamide gel as
previously described and stained with colloidal Coomassie
Brilliant blue.
Comparison of Inhibitory Effects of SLPI on High-HLT and
Low-HLT
In this assay, the inhibitory activity of SLPI on highHLT and low-HLT cleavage of HMWK was compared.

A 1:50 E:S

molar ratio (« a 1:53 ratio for high-HLT and a 1:331 ratio
for low-HLT based on the number of active sites) and a 1:100
E:I molar ratio (« a 1:105 ratio and a 1:662 ratio for highHLT and low-HLT, respectively, based on the number of active
sites) was used.

Five 1.5 ml microcentrifuge tubes each

containing 400 pi of assay buffer (0.1 M HEPES pH 7.5
containing 10 pM heparin, 10% glycerol, 0.05% Brij 35 and
0.02% NaN3) were incubated at room temperature for 30
minutes after the following additions:
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1)

no addition

2)

high-HLT (3.51 pmol or 3.33 pmol of active sites)

3)

high-HLT (3.51 pmol) and SLPI (351 pmol)

4)

low-HLT (3.51 pmol or 0.53 pmol of active sites)

5)

low-HLT (3.51 pmol) and SLPI (351 pmol)

HMWK (175.5 pmol) was added to all 5 tubes followed by a
second incubation for 60 minutes.

The reactions were

stopped by TCA precipitation as previously described and the
samples were analyzed by SDS-PAGE using an 8% 1.5 mm gel.
The proteins were visualized using colloidal Coomassie
Brilliant blue stain.
Tryptase cleavage of Laminin. Fibrinogen, and Fibronectin
Several naturally occurring proteins were tested as or
confirmed as substrates for one or both of the tryptase
isozymes.

These included fibrinogen (Schwartz et al.,

1985), HMWK (Maier et al., 1983), and VIP (Tam and Caughey,
1990), which had been reported in the literature as tryptase
substrates, and laminin and fibronectin, which had not been
previously tested.

Cleavage of HMWK and VIP by high-HLT and

low-HLT is described in another section.

In this

experiment, laminin, fibrinogen, or fibronectin (20 fig) were
tested as substrates for high-HLT.

Laminin contains 3

chains with a combined MW of approximately 1000 kDa.

The

stock solution contained 680 pg/ml (680 pmol/ml); therefore,
20 pmol egualed 20 fig.

Fibrinogen has a MW of 340 kDa.

The

stock solution contained 1 mg/ml (2.94 nmol/ml); therefore,

58.8 pmol equaled 20 /xg.

Fibronectin contains 2 chains with

a combined MW of 500 kDa.

The stock solution contained 600

Mg/ml (1.2 nmol/ml); therefore, 40 pmol equaled 20 ftg,
1:200 E:S molar ratio was used for each substrate.

A

Six 1.5

ml microcentrifuge tubes containing 200 til of assay buffer
(0.1 M HEPES pH 7.5 containing 10 mM heparin, 10% glycerol,
0.05% Brij 35, and 0.02% NaN3) and the

following amounts of

substrate and enzyme were incubated at room temperature for
30 minutes:
1)

20 pmol

of laminin

2)

20 pmol

of laminin and

3)

58.8 pmol

of fibrinogen

4)

58.8 pmol

of fibrinogen and 0.294 pmol of high-HLT

5)

40 pmol

6)

40 pmol of fibronectin

0,1 pmol ofhigh-HLT

of fibronectin
and 0.2pmol

of high-HLT

The reactions were stopped and the proteins precipitated
using cold 40% TCA as described under HMWK Cleavage.

Thirty

fil of IX SDS ammediol sample buffer containing 1% 0-ME was
added to the dried samples and 20 fil of the same sample
buffer was added to

10fil of MW standards followed by

heating at 95°c for

5 minutes and cooling.

Twenty /*! of

each sample were loaded on a 7% 1.0 mm gel and the samples
and standards were electrophoresed as described previously
and visualized with colloidal Coomassie Brilliant blue.
second gel, a Bio-Rad prepoured 4-20% polyacrylamide gel,
was run using the remainder of the samples and additional

A
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standards.

A Tris-glycine running buffer was used (25 mM

Tris, 208 mM glycine, 0.5% SDS pH 8.3) and the gel was run
at a constant voltage of 200 V.

The proteins were

visualized using the Bio-Rad Silver Stain kit.
Carboxvmethvl-papain Column Preparation
CM-papain column material was prepared by a
modification of a previously published method (Johnson et
al., 1987).

One hundred ml of SpectraGel A 6 agarose column

material was washed with cold 1.5 M Na2C03 and incubated with
25 g of CNBr dissolved in 25 ml of acetonitrile at room
temperature with stirring in a fume hood until the mixture
appeared uniform.

The column material was then washed

thoroughly on a Buchner funnel with cold dH20 followed by
0.1 M Na2HP04 pH 7.8 (coupling buffer).

Fifty mg of papain

(twice crystallized, Na acetate suspension) dissolved in 30
ml of coupling buffer was incubated with the column material
overnight at 4°C,

The mixture was warmed to room

temperature and 2 ml of ethanolamine was added (to block an
unreacted CNBr coupling groups) and allowed to react for 30
minutes, followed by washing the column material with one
liter of 0.2 M Na acetate 0.5 M NaCl pH 4.5 and one liter of
0.05 M Tris.

The Ajl0 of the initial wash solution was

checked and compared to the unreacted papain solution to
determine the amount of papain coupled to the column
material (23 mg).

The column material was washed with 0.2 M

Tris pH 8.5 and suspended in 100 ml of the same buffer.
Papain was activated with 0-ME at a final concentration of l
mM, which assures a free active site thiol group, followed
by the addition of 27.9 mg of ICH3C00H (dissolved in 1 ml of
1 M NaOH) for a final concentration of 1.5 mM and incubation
at room temperature for 15 minutes to carboxymethylate the
cysteine residues present in the papain.

The column

material was washed thoroughly with dH20 and then with 50 mM
Na2HP04 0,02% NaNj pH 7.5.
Kininogen Purification
HMWK was purified from frozen human plasma by a
previously published method (Johnson et al., 1987).
Approximately 200 ml of plasma was thawed by immersing the
bag in lukewarm water and the plasma was transferred to a
plastic beaker.

Inhibitors were immediately added to

prohibit plasma proteases from degrading the kininogens.
The inhibitors added were 10 mM benzamidine HCl (inhibits
trypsin-like serine proteinases), 40 /xg/ml polybrene (blocks
negatively charged surfaces), 2 mM EDTA (inhibits
metalloproteinases by chelating metal ions), 0.2 mM PMSF
(irreversibly inhibits serine proteases by binding to the
active site serine), and 0.2 mg/ml SBTI (inhibits serine
proteinases).

After adding N a d to a final concentration of

2 M, the plasma was centrifuged at 16,300 x g (5°C) for 30
minutes and the supernatant was incubated with 78 ml of
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carboxymethyl-papain Sepharose column material equilibrated
with 50 mM Na2HP04 2 M Nacl pH 7.5 containing 1 mM
benzamidine, 40 /jg/ml polybrene, 2 mM EDTA, 0.2 mM PMSF,
0.02% NaNj in a plastic flask for 45 minutes at room
temperature.

The column material was collected on a Buchner

funnel, washed with equilibration buffer and poured into a
siliconized glass chromatography tube.

The column was

further washed with equilibration buffer until the Ajio fell
below 0.01 followed by washing with 100 ml of 50 mM Na2HP04
pH 7.5 containing 2 mM EDTA, 0.1 mM PMSF, 0 .02% NaNj.

The

kininogens were eluted from the column with 50 mM Na2HP04 pH
11.5 containing 2 mM EDTA and 0.02% NaNj and 3 ml fractions
were collected at 2 minute intervals into plastic tubes
containing 125 fil of l M Na acetate pH 4.4 containing 4 mM
PMSF to achieve a final concentration of 0.2 mM PMSF and a
pH of 5.5.

The absorbance of the fractions was read at 280

nm and the appropriate fractions were pooled (50 ml) and
concentrated in an Amicon pressure cell using a 30,000 MW
cutoff membrane (YM-30) to 20 ml and the sample was diluted
to 50 ml with 10 mM Na acetate pH 5.5 containing 1 mM
benzamidine and 0.2 mM PMSF and the sample was concentrated
to 6 ml.

Three ml of the sample were loaded on a Mono Q 5/5

HPLC column equilibrated in 10 mM Na acetate pH 5.5 at 0,5
ml/minute and the column was washed with equilibration
buffer at 1.0 ml/minute until the Ajm reached zero.

LMWK

was eluted with a NaCl gradient of 0-0.25 M over 30 minutes

followed by HMWK elution with a 0.25-0.5 M NaCl gradient
over 5 minutes.

The remaining 3 ml of the concentrated

sample from the carboxymethyl-papain Sepharose column was
chromatographed on the Mono Q column in the same way.
fractions corresponding to the

The

peak were pooled and

analyzed by SDS-PAGE with reduction.

The HMWK pool produced

a major band with an M, of 114 kDa as expected for intact
HMWK and a contaminating band of M, 55 kDa and LMWK appeared
as a 67 kDa band.

The contaminant co-purified with HMWK,

even in the presence of 5 M urea, and most likely was the
amino terminal region of HMWK resulting from autolysis by
kallikrein during preparation and storage of the blood
plasma (Kato et al., 1981).

This band did not react with

antibodies specific for the carboxy terminal portion of
HMWK.
HMWK Cleavage
All cleavage reactions were performed in 1.5 ml
microcentrifuge tubes at room temperature.

To 1000 fil of

reaction buffer (0.1 M HEPES 10 jiM heparin 10% glycerol
0.05% Brij 0.02% NaN3 pH 7.5), 1.74 nmol (443 pg/ml) of HMWK
and the appropriate amount of enzyme was added.

A 1:50

molar ratio (enzyme:substrate) was used for high-HLT while a
1:1300 molar ratio was used for low-HLT, based on the number
of active sites of tryptase.

These enzyme-substrate ratios,

which were based on preliminary experiments, yielded similar

cleavage rates.

Aliquots of twenty pg of HMWK were

withdrawn at each of five time points, 5, 10, 20, 40, and 60
minutes, and the reaction was immediately terminated by
precipitating the proteins with either TCA or ethanol.

TCA

precipitation, used for the samples on the gels shown in
Figure 2, involved adding TCA to each sample for a final
concentration of 20% and incubating the samples on ice for 1
hour, followed by centrifugation and washing of the
precipitates twice with 700 pi of cold 10% TCA and twice
with 700 pi of cold acetone and drying at room temperature.
The TCA precipitation protocol used initially did not
recover some smaller fragments that were subsequently
detected when ethanol precipitation was used.

Ethanol

precipitation, used for the samples on the Western blot
shown in Figure 3, involved adding nine volumes of ice cold
absolute ethanol to each sample followed by incubation for
12 hours at -20°C. Precipitates were collected by
centrifugation at 14,000 rpm (4°C) for 5 minutes and were
dried at room temperature.
Sequencing of HMWK Fragment
HMWK (40 pg; 350pmol) was incubated with either 7 pmol
of high-HLT (E:S of 1:50) or 1.76 pmol of low-HLT (E:S of
1:200 based on protein concentration or 1:1326 based on
number of active sites) in assay buffer for 10 minutes at
room temperature (cleavage corresponds to the 10 minute time
period in Figure 2) followed by precipitation with cold
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trichloroacetic acid as described under HMWK Cleavage.
Eight pg of the sample were loaded in each of five lanes of
a 6% SDS-PAGE gel and then electrophoresed and
electroblotted onto Immobilon-P as described under
Electrophoresis and Western Blot Analysis.

The membranes

were lightly stained with 0.1% Coomassie R-250 in 50% MetOH
10% acetic acid (v/v), dried, and sent to Dr. Mark Lively at
Bowman Gray School of Medicine (Winston-Salem, NC) for amino
acid sequencing.
VIP Cleavage
Cleavage of VIP by the tryptase isozymes was performed
in 1.5 ml microcentrifuge tubes at room temperature.

Thirty

nmoles of VIP were added to 500 pi of reaction buffer and
24.7 pmoles of either high-HLT or low-HLT active sites (E:S
of 1:17000).

Equal aliquots were withdrawn from the

reaction mixture at 5, 10, 20, 30, and 60 minutes and 5 pi
of acetic acid was added to each aliquot to stop the
reaction, followed by the addition of 130 pi of 0.1% TFA
(HPLC buffer A ) .

The samples were then filtered and applied

to a Cu column at 0.5 ml/minute.

The column was eluted at

0.5 ml/minute with a 10-40% gradient of buffer B (0.1% TFA
in acetonitrile) over 20 minute and the absorbance was
monitored at 210 nm.
Amino Acid Analysis of VIP Cleavacfe Products
The peak at 24.34 minutes from the high-HLT cleavage of

VIP and the peak at 28.54 minutes from the low-HLT cleavage
of VIP were collected in separate microcentrifuge tubes.
The samples were transferred to HH03-cleaned 6 x 50 nun glass
tubes and dried in a SpeedVac for 45 minutes, then
hydrolyzed in an evacuated vial with 6 N HC1 at 110 °c for 23
hours.

Hydrolyzed samples and amino acid standards (500

pmol) were dried as before and PITC derivatized according to
the Pharmacia protocol.

This involved the addition of 10 fil

of MetOH:TEA:H20 (2:2:1) to each tube and drying followed by
addition of 20 fil of MetOH:H20:TEA:PITC (7:1:1:1) to each
tube and drying.

Immediately before use, samples or

standards were solubilized in 25 fil of HPLC buffer A (940 ml
of 140 mM sodium acetate trihydrate containing 0.05% v/v
triethylamine mixed with 60 ml of acetonitrile) and
chromatographed on a Haters Pico-Tag column at 1 ml/minute
with a 0-46% buffer B (60% acetonitrile in H20) convex
gradient (curve #5) over 15 minutes.

Quantification of the

amino acids was accomplished with Waters Maxima software on
an IBM/AT computer.

CHAPTER 3
RESULTS

Purification and Separation of the Two Tryptase Isozymes
Purification of tryptase from human lung tissue
produced two pools of activity with M, values of
approximately 29 kDa and 33 kDa (Figure 3).

The 29 kDa pool

(low-HLT) was obtained in small quantities (15% of high-HLT)
and was more difficult to purify.

A variety of columns and

loading/elution conditions were tried with the goal of
improving isozyme separation, purity and yield over previous
purification protocols, with little success.

A Dowex-lX

column was used to reduce the viscosity of the crude
extract.

Dowex binds heparin and other negatively charged

molecules while allowing tryptase to be collected in the
flowthrough.

The recovery of activity was 56% and the

viscosity was only slightly reduced.

This pool was dialyzed

and chromatographed on a heparin-Sepharose column and eluted
with increasing salt.

The binding capacity of the heparin-

Sepharose was low and about 50% of the activity was detected
in the flowthrough.

Two peaks of activity eluted from the

column but both contained numerous proteins (Figure 1 in the
Appendix).

An affinity column, p-aminobenzamidine agarose,

was also tried but also exhibited low binding capacity.
CPC extract was loaded on at pH 7.5, the pH at which
tryptase is most active but less stable than at
53
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Figure 3.

SDS-PAGE of High-HLT and Low-HLT Isozymes.

A, high-HLT (10 #ig); Lane B, low-HLT (10 /xg).

Lane

Samples and

standards were denatured and reduced before electrophoresis
on a 10% gel.

Molecular weight markers were, as indicated,

phosphorylase B (100 kDa), transferrin (78 kDa), BSA (68
kDa), igG (50 kDa), carbonic anhydrase (29 kDa), soybean
trypsin inhibitor (21 kDa), cytochrome c (12.75 kDa), and
Trasylol (6.5 kDa).

pH 6.1, and eluted with pH 4.5 buffer or 1 M NaCl buffer.
The yields of protein as detected by A3|0 were very low as
were the yields of activity (s 10%).

The sulfopropyl-type

cation exchange columns Spectra Gel SP and Mono s HPLC were
tried because the cation exchanger cellulose-phosphate bound
tryptase very well.

However, the binding capacities of

these columns were lower than cellulose-phosphate and the
NaCI in the sample had to be reduced to 0.2 M or less for
binding to occur.

Eventually, the best purification scheme

found utilized CPC treatment of crude extracts followed by
chromatography on butyl hydrophobic interaction
chromatography (HIC) and cellulose-phosphate columns.
Both tryptase isozymes, along with many other proteins,
bound to the butyl HIC column in 2 M (NH4)2S04 and eluted
together with a decreasing (NH^St^ gradient.

Elimination

of the (NH4)2S04 and reduction of the NaCl concentration of
the butyl pool by dialysis against MES buffer containing 0.3
M NaCI allowed subsequent binding of both isozymes to
cellulose-phosphate column material.

High-HLT eluted from

the cellulose-phosphate column with 10 pH heparin whereas
low-HLT did not elute with heparin but required 1 M NaCl for
elution.

Alternately, a gradient of 0-50 /jM heparin and 0.3

M-l.5 M NaCl dissociated both isozymes from the cellulosephosphate column, with high-HLT eluting first.

SDS-PAGE

analysis showed that some low-HLT preparations contained
minor contaminants, that coeluted from the cellulose-
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phosphate column, which required re-chromatography to
remove.

The presence of tryptase throughout the

purification procedure was monitored by a chromogenic
activity assay using the synthetic trypsin substrate CbzLys-SBzl.

The overall recovery of activity was usually

about 25% with the high M, fraction representing
approximately 85% of the total activity and the low M, form
accounting for 15% of the activity on Cbz-Lys-SBzl.

A

representative purification table is shown in Table 2, and
Figure 4 shows the stages of purification on SDS-PAGE.
Active site titration of the two tryptase isozymes with MUGB
showed that the high-HLT was 95% active, whereas the low-HLT
was only 15% active.
Structural Analyses of the Two Isozymes
Pealvcosvlation of Hlch-HLT and Low-HLT
Deglycosylation of the two isozymes was attempted in
order to get an indication of the carbohydrate content in
relation to the H, and to determine if the primary
difference in size between the isozymes was due to
glycosylation.

Treating both forms of tryptase that had

been TCA precipitated, dissolved in SDS buffer and reduced
with DTT, with N-Glycanase (a recombinant form of
endoglycosidase-F), yielded much sharper bands on SDS-PAGE,
but only high-HLT decreased noticeably in M, (an approximate
decrease of 1-2 kDa).

Low-HLT remained at the same relative

Table

2.

Purification of High-HLT and Low-HLT

from 500

g of Human Lung Tissue.

A

representative purification table for the purification of high-HLT and low-HLT shows an
ultimate combined recovery of activity of 25%, with high-HLT representing 84% of the total
activity.

The Activity is expressed as the increase in absorbance at 410 nm/minute/ml.

Specific Activity is defined as the Activity/A^.

The

The Fold Purification is based on the

increase in Specific Activity and the Percent Recovery is based on the Total Activity in each
pool (volume x activity) compared to the crude extract.

Total
Volume fmll

-^no-

Total
Activity

Specific
Activity

Fold
Purification

Percent
Recovery

Crude lung extract

460

5750

15272

2.7

1.0

100

CPC/{NH4>3S04 extract

975

3023

19403

6.4

2.4

127

110

275

13090

47.6

Heparin fraction

22

7.0

3212

NaCI fraction

12.5

1.5

375

Butyl pool

18

86

456

169

21

250

93

4

Cellulose-phosphate

U1
-o
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1005029-

2112.75Figure 4.

SDS-PAGE (10%) of the Progressive steps of

Purification of High-HLT and Low-HLT.

Lane A, crude lung

extract (20 /il); Lane B, activity pool from butyl column
before dialysis (10 fig), Lane C, activity pool from butyl
column after dialysis (10 fig); Lane D, activity pool from
the heparin elution of the cellulose-phosphate column (10
fig); and Lane E, activity pool from the NaCI elution of the
cellulose-phosphate column (10 /ig).

The samples and HW

standards were denatured and reduced before electrophoresis.
The gel was stained with colloidal Coomassie blue.
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MW but the profile of the band changed significantly (Figure
5A)*

High-HLT was also treated with N-Glycanase without

first TCA precipitating the enzyme and without denaturation
and reduction with SDS and 0-ME, respectively, in order to
test the effect of deglycosylation on the activity of highHLT.

SDS-PAGE analysis of this sample (Figure 5B) shows

only a slight reduction in M,.

The results of an activity

assay of 5 ^1 of the sample and the controls are presented
below:
Sample

AA1tA/mlnute

% Activity

Before treatment

0,2277

100

control

0.1574

69

Treated sample

0.1752

77

Both the control and the N-Glycanase-treated sample lost 2530% of the activity in the original sample, presumably due
to the incubation at 43 °c for 21 hours.

However, there is

no significant difference in activity level between the
control and the N-Glycanase-treated high-HLT.
Gel Filtration.

Another structural study carried out

was gel filtration to determine any differences in
quaternary structure between the two tryptase isozymes.
After calibrating a Sephacryl S-200HR column with Blue
dextran (MW » 2000 kDa; to determine the V„), IgG (MW = 150
kDa), BSA (MW = 67 kDa), and chymotrypsinogen A (MW = 25
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Figure 5 (A).

8D8-PAGE (10%) of High-HLT end Low-HLT

Deglycosylated Following Denaturation and Reduction.

Lane

A, high-HLT; Lane B, high-HLT treated (deglycosylated) with
N-Glycanase; Lane C, low-HLT; and Lane D, low-HLT treated
with N-Glycanase.

Samples were denatured with SDS and

reduced with B-ME before N-Glycanase treatment.
lane contained approximately 10 jug of protein.
Coomassie blue stain was used.

Each sample
Colloidal

The samples and MW

standards in A and B were reduced before electrophoresis.
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kOa

Std A

B Std

785029-

2112.756.5-

Figura 5 (B).

SDS-PAGE (10%) of High-ELT Daglycosylatad

Without Prior Denaturation and Reduction.

Lane A, high-HLT

(2.5 fig); Lane B, high-HLT (2.5 ftg) treated with NGlycanase.

The sample was not denatured or reduced before

deglycosylation.
stain.

The proteins were visualized using silver

kDa), a mixture of high-HLT and low-HLT was chromatographed
on the column.

The AII0 of the fractions were read and the

values were plotted vs. the fraction number, yielding, as
shown in Figure 6A, three distinct absorbance peaks with M,
of approximately 125 kDa, 55 kDa and 28 kDa.

An overlay of

the Agio of the fractions and the corresponding activities on
Cbz-Lys-SBzl showed that the peaks of activity corresponded
exactly with the A2W peaks (Figure 6B).

SDS-PAGE analysis

of the three peaks of activity showed that the first and
second peaks contained high-HLT and the third peak contained
low-HLT (Figure 7).

These data indicated that high-HLT may

exist primarily as a tetramer, with a H, of about 125 kDa,
while low-HLT may exist as a monomer, with a H, of about 28
kDa.

There may also be a dimeric form (M, of 55 kDa)

containing two heterologous subunits.

Western blot analysis

of these pools was somewhat inconclusive.

The two high M,

pools migrated out of the gel onto PVDF or nitrocellulose
membrane and reacted with the polyclonal anti-HLT antibody
(Figure 8).

The low M, pool, however, did not migrate out

of the gel under various transfer conditions and therefore
was not immunologically analyzed.
Inhibition Studies of Hioh-HLT and Low-HLT Using Several
Trvosin Inhibitors
Two types of inhibitor assays were done, one using the
small synthetic substrate Cbz-Lys-SBzl and one using the
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Figure 6 (A). Chromatogram of a Mixture of High~HLT and LowHLT on a Sephacryl 8200-HR Gel Filtration Column with HW
standards.

A standard solution of 2 mg each of igG (MW =

150 kDa), BSA (MW = 67 kDa) and chymotrypsinogen A (MW = 2 5
kDa) was chromatographed on a 1.5 x 88 cm gel filtration
column at 0.5 ml/min. and the A],0 of each fraction was read
and graphed.

The graph was overlaid on a chromatogram of

the A^o of fractions collected after a mixture of high- and
low-HLT (1-1.5 mg of total protein) was applied to the
column.

The V0 had previously been determined to be 60 ml

by chromatography of 500 fxl of a saturated solution of blue
dextran (MW = 2000 kDa).
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Figure 6 (B).

Activity

Chromatogram of a Mixture of High-HLT and

Low-HLT on a Sephacryl S200-HR Gel Filtration Column with
Activity Overlay.

The activities of the high- and low-HLT

fractions were measured by microtiter plate assay using CbzLys-SBzl as the substrate and the A4t0/minute was graphed
over the A^q of the fractions.
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Figure 7*

SDS-PAGE (10%) of Peaks Collected from

Chromatography of High-HLT and Low-HLT Mixture on Gel
Filtration Column.

Lane A, Pooled fractions 62-74 (10 fig);

Lane B, pooled fractions 78-84 (10 fig); Lane c, pooled
fractions 89-91 (10 fig).

The samples and KW standards were

reduced before electrophoresis and were visualized with
colloidal Coomassie blue.
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Figure 8.

Western Blot end coomaaaie stained Membrane Gal

Filtration Peaks.

Lane A, Pooled fractions 62-74 (0.5 fig);

Lane B, pooled fractions 78-84 (5 jig); Lane C, pooled
fractions 80-91 (5 fig).

The proteins were electrophoresed

on a 10% SDS-PAGE gel with reduction, transferred to a PVDF
membrane, blocked with BSA, incubated with 1:2000 rabbit
anti-HLT antibody, washed and incubated with 1:2000 goat
anti-rabbit IgG antibody conjugated with alkaline
phosphatase, and developed with NBT/BCIP. Lanes D, E, and P
were duplicates of lanes A, B, and c, respectively.

The

samples were electrophoresed as above and the protein was
transferred to PVDF membrane and visualized by staining with
0,1% cooraassie R-250 in 25% MetOH/10% oAc (v/v).
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large protein substrate HMWK.

The inhibitors tested

using Cbz-Lys-SBzl as the tryptase substrate were SLPI,
ecotin, ASTI, APPI, Ial, CMTI-III, and Argl5Glui2aprotinin.
The assays with SLPI, ecotin and ASTI were done using a 1:10
E:I ratio based on protein concentration; the assays with
APPI, Ial and ArglsGluJIaprotinin were done using a 1:100 E:I
ratio based on protein concentration; and the assays with
CMTI-III were done using a 1:50 E:I based on the number of
active sites of enzyme.

The results of the individual

assays with the corresponding controls, summarized in Table
3, show that none of the inhibitors demonstrated significant
inhibition of tryptase.
The second type of assay, using HMWK as the substrate,
produced results showing that one inhibitor, bovine a2M, may
inhibit high-HLT (it was not tried with low-HLT), and one
other inhibitor, SLPI, showed definite inhibition of both
isozymes.

The other inhibitors tested included rat 0,13,

Arg15Glunaprotinin, APPI, Ial, ASTI, and CMTI-III.

Assays

with a3M and a,l3 used E:I molar ratios of one, based on the
number of active sites of tryptase; assays with
Arg13GluHaprotinin, APPI, Ial, ASTI SLPI, and CMTI-III were
performed at an E:I ratio of 1:100, based on protein
concentration.
Previous studies had indicated that human tryptase was
not inhibited by human a2M nor did tryptase cleave the bait

Table 3 .

Inhibition Assays of High-HLT Using Various Trypsin Inhibitors.
\

performed at room temperature using Cbz-Lys-SBzl as the substrate.
set up separately as described in Materials and Methods.

All assays were

*

Each set of assays was

An E:I ratio of 1:100 was used for

the trypsin controls and incubated for 20 minutes before addition of the substrate.

Control - Test of Inhibitor Activity on Trvnsin
a

Porcine Trypsin Control
"

+ APPI

”

+ Ial

/minute

% Activity

0.4088

100

0.0068
0.0446

"

+ ArgIJGlu52aprotinin

0.0030

"

+ ASTI

0.0267

"

+ SLPI

0.2226

10 minutes**
AAm /min.

1.7
'

11
<1
6.5
54*

60 minutes

% Act.

AAir/min.

% Act,

Tryptase Control

0.4820

100

0.3655

100

SLPI

0.4092

85

0.2962

81

ASTI

0.4457

92

0.3443

94

Ecotin

0.4165

86

0.3246

89
C7\
03

Table 3. (cont.)
PH 7.5*

AA^n/minute

% Activity

Tryptase Control

0.4451

100

APPI

0.4271

96

Ial

0.453 8

102

pH 3.0++
AA.tft/minute

PH 8.5+*

% Activity

A A |in/minute

% Activity

Tryptase Control

0.4338

100

0.4256

100

SLPI

0.4309

99

0.4148

97

ASTI

0.4462

103

0.4267

100

Ial

0.4506

104

0.4662

109

APPI

0.4221

97

0.4288

101

Arg^Glu^aprotinin

0.4230

98

0.4381

103

’Porcine trypsin is not as well inhibited by SLPI as bovine trypsin (Smith and Johnson, 1985).
"Times refer to the length of incubation of enzyme (E) and inhibitor (I) before addition of
substrate.

An E:I ratio of 1:10 was used for these assays.

+E:I ratios of 1:100; 3 hour incubation of E and I before addition of substrate.
++E:I ratios of 1:100; 20 minute incubation of E and I before addition of substrate.
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region (D. A. Johnson and T. J. Smith, unpublished data).

A

limited experiment using bovine o2M and high-HLT was
inconclusive (see Figure 2 in the Appendix).

The cleavage

of HMWK was used as the control in this experiment, but was
not carried out to completion; therefore, analysis of the
inhibition of cleavage in the sample lanes was difficult.
However, there was a discernable difference between the
control and the sample containing the inhibitor, ajti,
suggesting some degree of inhibition of high-HLT by cr2M.
Additional experiments using high-HLT and low-HLT
(independently) are needed to determine more definitively
the extent of inhibition, if any, of the two tryptase
isozymes by or2M.
Inhibition of human mast cell tryptase by SLPI had been
previously suggested (Fritz, 1988), but no supportive data
was provided.

Therefore, SLPI was tested as an inhibitor of

both human tryptase isozymes.

SLPI inhibition of high-HLT

and low-HLT using HMWK as the substrate is shown in Figure
9.

The

cleavage of HMWK was allowed to proceed for 60

minutes (presumably to completion) and, although over 6
times the number of active sites of high-HLT as low-HLT were
used, only the low-HLT control cleaved all of the substrate.
Subsequently, it was found that low-HLT was 25 times more
active on HMWK than high-HLT.

Low-HLT also appeared to be

more thoroughly inhibited by SLPI than high-HLT; however, a
six-fold higher E:I ratio was used for low-HLT, based on the
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Figure 9.

SDS-PAGE (a%) of the Inhibitory Effects of SLPI

on High-HLT and Low-HLT.

Lane A, HMWK (20 fig, 175.5 pmol);

Lane B, HMWK and high-HLT (3,51 pmol); Lane c, HMWK, highHLT and SLPI (351 pmol); Lane D, HMWK and low-HLT; Lane E,
HMWK, low-HLT and SLPI.

The cleavages represented in lanes

B and D were allowed to proceed for 60 minutes at RT before
being TCA precipitated for analysis.

The inhibitory effects

shown in lanes C and E were the result of incubation of the
enzyme (HLT) and inhibitor (SLPI) at RT for 30 minutes
followed by addition of substrate (HMWK) for 60 minutes
before TCA precipitation.

The samples and MW standards were

reduced before electrophoresis and were visualized with
colloidal Coomassie blue.

72
number of active sites, because the experiment was performed
with equal amounts of enzyme protein prior to active site
titration.

Therefore, although a comparison of inhibitory

activity of SLPI on high-HLT and low-HLT was not performed,
it was clear that both isozymes were inhibited by SLPI.
Argl5Glu5:aprotinin had been reported to inhibit tryptase
in the degranulation supernatants of human tonsilar mast
cells (Dietze et al., 1990); therefore, we tested this
modified trypsin inhibitor as an inhibitor of purified
tryptase.

As shown in Figure 10, no inhibition of high-HLT

by ArglJGlui2aprotinin was seen at pH 7.5 or 9.1, while the
activity of trypsin on HMWK was completely inhibited by
Arg13GluMaprotinin at pH 7,5.
Testing of Several Biological. Molecules as Tryptase
Substrates
Investigation of Laminin. Fibrinogen, and Fibronegtln_as
Tryptase Substrates.

Laminin, fibrinogen, and fibronectin

are all fibrous proteins or precursors of fibrous proteins.
Fibrinogen is involved in the later stages of the blood
coagulation cascade and is converted to fibrin, which
aggregates to form a thrombus, upon cleavage by thrombin.
Both fibrinogen and fibronectin are involved in the
enhancement of blood clotting, whereas both fibronectin and
laminin are classified as adhesive proteins involved in cell
adhesion to the extracellular matrix (Hynes, 1985).

Also,
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Figure 10.

B C

D

E F G Std

SDS-PAGE (7%) of the Inhibitory Effects of

Arg,JGlunaprotinin on High-HLT and Trypsin at pH 7.5 and 9.1.
Lane A, HMWK (20 fig, 176 pmol); Lane B, HMWK and trypsin
(0.88 pmol) at pH 7.5; Lane C, HMWK, trypsin and
Arg,5GluMaprotinin (88 pmol) at pH 7.5; Lane D, HMWK and
high-HLT (1.76 pmol) at pH 7.5; Lane E, HMWK, high-HLT and
Arg,5Gluwaprotinin (176 pmol) at pH 7.5; Lane F, HMWK and
high-HLT at pH 9.1; Lane G, HMWK, high-HLT and
Argl5Glunaprotinin at pH 9.1.

Inhibitor and enzyme in lanes

C, E and G were incubated at RT for 20 minutes before
addition of substrate and a second incubation at RT for 30
minutes followed by TCA precipitation.

Samples and MW

standards were reduced before electrophoresis were
visualized with colloidal Coomassie blue.

both laminin and fibronectin contain relatively high numbers
of Lys and Arg residues (Timpl et al., 1979), making them
good possible candidates as tryptase substrates.

Tryptase

in the presence of heparin had been reported to cleave both
the a and £ chains of fibrinogen (Schwartz et al., 1985) and
fibronectin had been shown to be cleaved by tryptase in the
presence of heparin (Smith, 1985).

Therefore, laminin,

fibronectin, and fibrinogen were all exposed to high-HLT and
analyzed by SDS-PAGE with reduction.

The results of these

experiments were not definitive due to the poor quality of
the electrophoresis gels, which are only presented in the
Appendix.

The data (Figure 3A in the Appendix) indicate

that fibrinogen was cleaved by high-HLT, as evidenced by the
appearance of a new band at approximately H, 65 KDa in the
tryptase-treated sample.

This agrees with the initial

results obtained by Schwartz et al. (1985), which showed the
production of a band of M, 65 kDa after a brief exposure of
fibrinogen to tryptase, and the disappearance of that band
and concurrent appearance of smaller bands following
prolonged exposure.

While no cleavage of either laminin or

fibronectin was apparent in Figure 3A, a difference in
banding pattern between the tryptase-treated and untreated
fibronectin samples was detectable in Figure 3B.

This

gradient gel ran and stained poorly, but still clearly
showed an additional band of about M, 45 kDa in lane 7 when
compared to lane 6.

Again, no cleavage of laminin was
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detectable.

Additional analysis of the effect of high-HLT

on laminin and fibronectin is needed to confirm the above
results, and investigation of the effects of low-HLT on all
three proteins is also necessary.
Cleavage of HMWK with High-HLT and Low-HLT
HMWK is a plasma protein which consists of a heavy
chain, composed primarily of three cysteine proteinase
inhibitor domains, and a light chain, containing a
histidine-rich region that includes the procoagulant
activity, separated by bradykinin (refer to Figure 13).
Although the three-dimensional structure of HMWK is unknown,
it seems likely that the highly charged light chain assumes
a conformational structure that makes it readily available
for interaction with other molecules, as it has been shown
that this part of the molecule is responsible for binding to
anionic surfaces (DeLa Cadena and Colman, 1992).

Cleavage

of HMWK by high-HLT or low-HLT produced different
fragmentation patterns on SDS-PAGE (Figure 11).

Several

smaller fragments generated by low-HLT failed to precipitate
with 20% TCA, but were subsequently detected by using
concentrated samples and performing SDS-PAGE without
precipitating the samples (Figure 4 in the Appendix).

Some

of these smaller fragments were also detected using ethanol
instead of TCA to precipitate the samples (data not shown).
This observation is consistent with the small fragments
being from the carboxy terminal region that is rich in basic

amino acid residues, and therefore may be less likely to
precipitate in an acidic environment.

High-HLT cleavage of

HMWK resulted initially in two major bands of M, 65 kDa and
46 kDa, with the 46 kDa fragment disappearing by 40 minutes
(Figure 11A ) . In contrast, low-HLT cleavage of HMWK produced
a minor band of M, 100 kDa and two major bands of M, 75 kDa
and 65 kDa.

By 40 minutes, only the 65 kDa fragment was

visible in Figure 11B.

Western blot analysis of these

products was performed after ethanol precipitation using a
monoclonal antibody to the light chain of HMWK to determine
which were the carboxy terminal fragments for sequencing.
As shown in Figure 12, a single 46 kDa fragment produced by
the action of high-HLT on HMWK reacted strongly with the
antibody, whereas low-HLT produced multiple fragments that
reacted only weakly with the c-terminal antibody, including
many fragments of less than 50 kDa, indicating numerous
nonspecific cleavages in the HMWK light chain by low-HLT.
Limited sequencing of several cleavage fragments was
performed by Mark Lively at Bowman Gray School of Medicine
in Winston-Salem, NC, using an Applied Biosystems gas phase
sequencer.

In order to obtain a better understanding of the

equipment and procedures used in automated sequencing and
analysis, I went to Bowman Gray and observed the sequencing
of these fragments.

The results of sequencing the 46 kDa

fragment from the high-HLT reaction indicated an amino
terminal sequence of Asp-Gln-Gly-Xaa-Gly-Xaa-Gln,
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Time Course SDS-PAGE of HMWK and Products after

Cleavage vith High-HLT and Low-HLT.

Lanes are labeled with

the length of cleavage reaction in minutes, which was
stopped by TCA precipitation.

Samples of 5 fig were loaded

in each well of the 6% SDS-PAGE gel with reduction and the
bands were visualized with Coomassie Blue staining.

A, HMWK

(5 /igf 219 pmol) cleaved with high-HLT (4.4 pmol; 1:50 E:S
based on protein concentration) ; B, HMWK cleaved with lowHLT (1.1 pmol; 1:200 E:S based on protein concentration)
Molecular weight markers are the same as in Figure 3.
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Western Blot of HMWK and Cleavage Products with

High-HLT and Low-HLT.

Lane A, HMWK and cleavage products

(20 fig, 174 pmol) after a 20 minute cleavage with high-HLT
(3.48 pmol; 1:50 E:S based on protein concentration); Lane
B, HMWK and cleavage products (20 ng, 174 pmol) after a 20
minute cleavage with low-HLT (0.87 pmol; 1:200 E:S based on
protein concentration).

Reactions were stopped and products

were collected by ethanol precipitation.

The samples and MW

standards were reduced, electrophoresed on an 8% SDS-PAGE
gel and transferred to a PVDF blotting membrane.

A

monoclonal antibody to the light chain (C-terminus) of HMWK
was used as the primary antibody.

Antibody binding was

visualized using Protein G Gold and silver enhancement.
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corresponding to HMWK residues Asp4JJ-Gln-Gly-His-Gly-HisGln43t in the light chain of HMWK (Figure 13).

Thus, high-

HLT cleaves HMWK between Arg431 and Asp4]1 (or Arg«9 and Asp4JQ
of prekininogen; Takagaki et al., 1985).

Attempts to

sequence the 75 kDa and 65 kDa bands produced by the low-HLT
reaction were unsuccessful.

Presumably they contain the

amino terminus of HMWK, which is unavailable to Edman
degradation due to the presence of an amino terminal 5oxoproline (Kellermann et al., 1986).

Due to the multiple

c-terminal fragments produced by low-HLT, determination of a
primary cleavage site was not possible.
cleavage of VIP bv High-HLT and Low-HLT
VIP cleavage by each of the two tryptase isozymes
produced different chromatographic profiles when analyzed by
C]t reverse-phase HPLC.

As shown in Figure 14, the heights

of the residual VIP peaks were approximately the same at 10
minutes with low-HLT (Figure 14C) and at 20 minutes with
high-HLT (Figure 14B).

The enzyme/substrate ratios (based

on the number of tryptase active sites) were the same in
these experiments, indicating that low-HLT cleaved VIP at
twice the rate of high-HLT.

The initial major cleavage

product resulting from cleavage by high-HLT eluted at 24.4
minutes and the initial major cleavage product resulting
from cleavage by low-HLT eluted at 28.4 minutes, relative to
native VIP at 29.1 minutes (Figure 14A).

Although both
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FROCOAGVLANT

DOMAINS
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43<

HIGH-HLT
CLEAVAGE
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Figure 13.

Schematic Representation of HMWK showing the

Primary Cleavage site by High-HLT.

Forty fig (350 pmol) of

HMWK was cleaved with 7 pmol of high-HLT (E:S of 1:50) for
10 minutes and 8 fig of the sample were electrophoresed in
each of five lanes of a 6% SDS-PAGE gel and transferred to
an Immobilon-P membrane.

Limited sequence analysis of the

46 kDa fragment from this cleavage was performed using
automated Edman degradation.

The resulting amino terminal

sequence of Asp-Gln-Gly-Xaa-Gly-Xaa-Gln corresponded to a
primary site of cleavage by high-HLT at Arg<n in the
procoagulant region of the light chain of HMWK.
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Figure 14.

Reverse-phase HPLC chromatograms of VIP and the

cleavage products generated by the activity of high-HLT and
low-HLT.

A, native VIP (20 ftg or 6 nmol); B, VIP (20 ng)

after exposure to 0.346 pmol of active high-HLT (1:17340
E:S) for 20 minutes; C, VIP (20 /xg) after exposure to 0.346
pmol of active low-HLT for 10 minutes; D, VIP (20 jig) after
exposure to 0.346 pmol of active high-HLT (1:17340 E:S) for
60 minutes; and E, VIP (20 jig) after exposure to 0.346 pmol
of active low-HLT for 60 minutes.

Five /il of glacial acetic

acid and 130 jxl of 0.1% TFA were added to each sample before
chromatography on a CIS column and elution with a 10-40%
acetonitrile linear gradient.
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chromatographic profiles changed as the reactions proceeded
to completion, they never became identical (Figure 14D & E),
further indicating a difference in substrate specificity.
Amino, Acid Analysis of VIP Cleavage Products
The initial major cleavage product of the activity of
each of the tryptase isozymes on VIP was collected and amino
acid analysis was performed.

The results, shown in Table 4,

suggest that the primary cleavage site for high-HLT is Arg14,
which agrees with the findings of Tam and Caughey (1990);
and, although the amino acid analysis results were not as
clear for low-HLT, the data suggest that the primary
cleavage site for low-HLT is Arglz.

These data correspond to

fragments of 1-14 for the high-HLT product and 13-28 for the
low-HLT product.

Figure 15 shows the sequence of VIP and

the proposed cleavage sites for high-HLT and low-HLT.
Attempted Peptide Mapping of the Tryptase Isozymes
Peptide mapping of the two tryptase isozymes would
provide some very important information for determining
whether these isozymes are the gene products of any of the
cDNAs cloned from human mast cells.

Peptide mapping

involves cleaving a protein at certain points and performing
limited sequencing of the peptides produced.

Peptide

mapping of the tryptase isozymes was attempted using Lys-C
(endoproteinase Lys-C from Promega), which cleaves proteins
on the carboxyl side of Lys residues, and CNBr, which

Table l.

Amino Acid Analysis of the Initial Products
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Resulting from the cleavage of VIP with High-HLT and LowHLT.

The peaks corresponding to the two initial products

(see Figure 5B and 5C) resulting from the cleavage of VIP
with each of the tryptase isozymes were hydrolyzed, PITC
derivatized, and analyzed using the Waters Pico-Tag method.
An amino acid with a theoretical yield of one was chosen to
represent an actual yield of one and all other pmol values
were divided by that pmol value to determine their actual
yields.

The theoretical yields represent VIP residues 1-14

corresponding to the high-HLT initial product and VIP
residues 13-28 corresponding to the low-HLT initial product.
Hioh-HLT Initial Peak
Actual

Theoretical

ttJBQlqa

Yield

_ Yield

Asp

32

2.9

3

Glu

2

0.2

0

Ser

18

1.6

1

Gly

4

0.4

0

His

26

2.4

1

Arg

23

2.1

2

Thr

13

1.2

2

Ala

13

1.2

1

Tyr

11

1.0

1

Val

9

0.8

1

Met

1

0.1

0

Cys & lie

6

0.5

0

Leu

13

1.2

1

Phe

10

0.9

1

Lys

1

0.1

0

Table 1.

Amino Acid Analysis of the Initial Products
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Resulting from the cleavage of VIP with High-HLT and LowHLT. (Continued)
Low-HLT Initial Peak
Actual

Theoretical
Yield

p moles

Yield

Asp

26

3.7

2

GlU

6

0.9

1

Ser

4

0.6

1

Gly

2

0.3

0

His

2

0.3

0

Arg

7

1.0

1

Thr

6

0.9

0

Ala

8

1.1

1

Tyr

10

1.4

1

Val

3

0.4

1

Met

4

0.6

1

Cys & lie

8

1.1

1

Leu

15

2.1

3

Phe

2

0.3

0

Lys

15

2.1

3
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25
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chemically severs proteins at Net residues.

These means of

cleavage were chosen to try to compare the two isozymes to
the amino acid sequences encoded by the a and 0 tryptase
cDNAs cloned from lung mast cells, which exhibit differences
in the number of these two amino acids.

Several months were

spent on this set of experiments with no significant
results.

However, it was determined that tryptase is

apparently resistant to cleavage by Lys-C, as evidenced by a
lack of decrease in M, of tryptase on SDS-PAGE after
exposure to Lys-C.

Intact tryptase completely disappears on

SDS-PAGE after exposure to CNBr, but successful
chromatography of the products on reverse-phase HPLC was
never achieved.

C„ and C,( columns were tried with a variety

of gradients and two different buffer systems (0.1%
TFA/acetonitrile buffer system and 6 mM HCl/acetonitrile
buffer system) without any positive results.

CHAPTER 4
DISCUSSION

Purification and Separation of the Trvntase Isozvmes
Purification and separation of the tryptases proved to
be somewhat difficult to achieve.

The main problems

encountered were low yields (an average of 25% total
recovery of activity) and unequal amounts of the two
isozymes (about 5 times more high-HLT than low-HLT based on
protein concentration; about 32 times more high- than lowHLT based on number of active sites).

Low-HLT was also more

difficult to purify to homogeneity, nearly always containing
some low M, contaminants that were difficult to remove and
frequently containing a very small amount of high-HLT.
Cetylpyridinium chloride treatment of crude extract greatly
reduced the viscosity of the extract by precipitating
mucopolysaccharides and nucleic acids.

Chromatography on

butyl HIC followed by cellulose-phosphate ion exchange
chromatography produced the highest yields and most
consistent separation of the isozymes.

However, an

inhibitor column, such as SLPI or ArgIJGlunaprotinin, may
improve enzyme purity and yield.

Elution of high-HLT from

cellulose-phosphate with heparin suggests that high-HLT has
a high affinity for heparin, whereas low-HLT required high
salt for elution, suggestive of low heparin affinity.
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Chromatography of crude extracts on heparin-Sepharose with
Western blot detection has shown that only high-HLT binds to
heparin (Burnette-Vick, unpublished data).
Structural characterization of the Isozvmes
Previous preparations of human mast cell tryptase have
contained two bands in the 29-35 kDa range differing by 2-5
kDa upon SDS-PAGE.

Because gel filtration chromatography of

these tryptase preparations in the past yielded estimated
molecular sizes of 135-144 kDa (Schwartz et al., 1981a;
Smith et al., 1984), it was assumed that tryptase was a
tetramer containing two slightly different active subunits.
Assuming that tryptase actually exists as a tetramer in
vivo, separation of the two active forms of tryptase implies
that the tetramer is composed of homologous subunits, rather
than a mixture of the two bands seen on SDS-PAGE.

Gel

filtration of the two forms of tryptase separated in this
lab has indicated that high-HLT probably exists as a
tetramer (approximate M, of 125 kDa) whereas low-HLT may
exist as a monomer (approximate M, of 28 kDa).
Low-HLT appears to have a lower affinity for heparin,
relative to high-HLT, providing additional evidence of
structural differences in the two forms.

Rat tryptase does

not bind heparin (Braganza and Simmons, 1991) and it has
been shown that mouse tryptase also lacks this affinity
(Johnson and Burnette-Vick, unpublished data).

Heparin
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binding motifs with the sequences BBXB and BBXXB have been
noted (where B is Lys or Arg; Blankenship et al.f 1990) and
it has hypothesized that R^-V-R^-D-R13 represents a new
heparin binding motif of the sequence BXBXB (D. Johnson,
unpublished data).

This sequence is found in HST-3 and HLT-

a, but is missing from HST-l and HLT-0/HST-2 (Figure 16).
Molecular modeling of the tryptases has shown the
presence of two insertions not present in trypsin, one on
either side of the active site (Figure 17), that may
restrict access to the active site by bulky substrates or
inhibitors, while allowing small molecules or loop
structures to reach the active site (Johnson and Barton,
1992).

Figure 17A shows a space filling model of human skin

tryptase 1 with the two insertions shown in orange and red
and the active site Ser and His in green and yellow,
respectively.

Another angle of this molecule is shown in

Figure 17B which exposes the Asp residue at the bottom of
the S, substrate binding pocket.

This may explain in large

part the high degree of substrate specificity and resistance
to most inhibitors displayed by the tryptases.

This

information will be useful in future investigations of the
interaction of tryptase with inhibitors such as SLPI and
substrates such as HMWK and VIP.
Another interesting observation was that there was a
difference between the two isozymes in their migration out
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HST-1
HST-2/HLT-0
HST-3
HLT-a
DMCT
MMCT-l
MMCT-2
Trypsin
Chymotrypsin

Figure 16.

1
11
21
31
I
!
!
!
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGG
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGG
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGG
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGG
IVGGREAPGSKWPWQVSLRLKGQYWRHICGG
IVGGHEASESKWPWQVSLRFKLNYWIHFCGG
IVGGQEAHGNKWPWQVSLRAndtYWMHFCGG
IVGGYTCGANTVPYQVSLN SGY HFCGG
IVNGEEAVPGSWPWQVSLQDKTGF HFCGG

Heparin
Binding
?
?
?
?
?
No
No
No
No

Amino terminal sequence alignment of the mast

cell tryptases showing the sequences of the tryptases in
comparison to those of trypsin and chymotrypsin.

HST-1,

human skin tryptase 1; HST-2/HLT-0, human skin tryptase
2/human lung tryptase beta; HST3, human skin tryptase 3,
HLT-a, human lung tryptase alpha; MMCT-l, mouse mast cell
tryptase 1; MMCT-2, mouse mast cell tryptase 2; DMCT, dog
mast cell tryptase; trypsin, bovine trypsin, chymotrypsin,
bovine chymotrypsin.

The arginine and lysine residues of

the potential heparin binding motif site are in bold print.
The putative Asn-1inked glycosylation site in MMCT-2 is in
bold lower case print.
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m

m

m

Figure 17 A.

Space filling model of HST-1 (Johnson and

Barton, 1992) constructed on the crystal structure
coordinates of trypsin.

The active site Ser is colored

green and the active site His residue is yellow.

The

smaller insertion of four amino acids (residues 20 through
26) is colored orange and the larger insertion (residues 164
through 174) is colored deep red.

Also, the proline-rich

hydrophobic region of tryptase (residues 139 through 145) is
colored purple.

The nitrogen of the putative Asn-linked

glycosylation site (residue 203) is colored blue/green and
is just visible at the top of the model.
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pp$t?i

Figure 17 B.

Another view of the space filling model of

human skin tryptase 1 with insertion loops colored orange
(20-26) and deep red (164-174) as in Figure 17 A.

This view

shows Asp 188 at the bottom of the S, substrate binding
pocket colored dark purple.

The active site Ser and His

residues are green and yellow, respectively.

The proline-

rich region and the Asn glycosylation site are colored
purple and blue/green, respectively, as in Figure 17 A.
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of gels onto PVDF and nitrocellulose blotting membranes.
The reason underlying this difference has not been
elucidated, but suggests further structural differences.
Isoelectric focusing studies on the enzymes might produce
data pertinent to this discrepancy.
Vanderslice et al. (1990) presented evidence supporting
the existence of multiple tryptase genes, and it is possible
that high-HLT and low-HLT correspond to the gene products of
the two tryptase sequences that have been derived from human
lung cDNAs, tryptase-a and tryptase-j3 (Miller et al., 1989
and 1990).

Tryptase-a is 244 amino acids in length with two

putative glycosylation sites per subunit, whereas tryptase-j3
is 245 amino acids in length with only one putative
glycosylation site.

Since tryptase-a with two glycosylation

sites would probably have a higher M, than tryptase-/S, highHLT may correspond to a while low-HLT may correspond to 0.
Confirmation of this must await further structural
characterization of the two isozymes.
Functional Differences of the Trvotase Isozvmes
It has been previously reported that the activity of
human tryptase is dependent on its interaction with heparin
(Smith et al., 1984; Schwartz et al., 1990).

However, if,

as preliminary data suggest, low-HLT exists as a monomer and
has a low affinity for heparin, its activity may be
regulated in an entirely different manner from high-HLT.

No
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endogenous inhibitors of tryptase have been reported;
therefore, a number of trypsin inhibitors were tested for
activity against tryptase.

The inhibitors tested differed

with respect to size, source and PI amino acid residue,
which makes elucidation of the characteristic(s) responsible
for tryptase inhibition more difficult.

None of the

inhibitors with an Arg residue in the active site inhibited
tryptase, whereas SLPI, which contains a Leu in the active
site, inhibited both tryptase isozymes.
All of the inhibitors tested are known to inhibit
trypsin and some are known to inhibit other proteases as
well.

Ecotin, a trypsin inhibitor isolated from E. coll,

contains 142 amino acids, has a subunit MW of 17 kDa and is
active as a dimer (McGrath et al., 1991).

In addition to

trypsin, ecotin also inhibits chymotrypsin and neutrophil
elastase, with Met*4 in the PI position of the inhibitory
site (McGrath et al., 1991).

This active site residue is

somewhat unusual for trypBin and elastase inhibitors, which
normally have Lys or Arg and Leu or Val, respectively, in
their active site (McGrath et al., 1991).

However, a,-

proteinase inhibitor, a plasma protein that inhibits
neutrophil elastase, has a Met in its active site and also
inhibits trypsin and chymotrypsin (Johnson and Travis,
1978), but does not inhibit tryptase.
SLPI is a monomeric protein containing 107 amino acid
residues with a MW of 11,726 Da.

It is found in various
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mucous-containing body fluids and also exhibits strong
inhibitory effects on several proteases, including bovine
trypsin and chymotrypsin, leukocyte elastase, cathepsin G,
and chymase (Fritz, 1988; Van-Seuningen and Davril, 1991).
Its activity against porcine trypsin, however, is reduced
compared to bovine trypsin (Smith and Johnson, 1985).

The

active inhibitory site has been determined to be Leu73 for
all proteases that interact with it (Eisenberg et al., 1990;
Van-Seuningen and Davril, 1991), similar to the peculiar
inhibitory activity of ecotin.
ASTI is isolated from the porcine roundworm Ascaris
suum and has a MW of 6880 Da (Peanasky et al., 1987).

APPI

is part of the Alzheimer's amyloid 0-protein precursor and
blocks proteases that cleave at basic residues (Hynes et
al., 1990).

It has a MW of 6416 Da, is 58 amino acids in

length, with an Arg,J P, active

site (Hynes et al., 1990).

Ial is a large protein complex found in human plasma
that is made up of three chains— two heavy chains of
approximately MW 66 kDa each, designated as subunits 0 and
7 , and a light (a) chain of MW 46 kDa that contains the
inhibitory activity (Gebhard et al., 1990; Potempa et al.,
1989; Salier, 1990).

The light chain, also known as bikunin

or HI30, has two active inhibitory sites, one with a PI Arg
and one with a PI Met, and inhibits trypsin, chymotrypsin,
neutrophil elastase, plasmin, and acrosin (Potempa et al.,
1989; Salier, 1990).

The function of the 0 and 7 subunits
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is unknown (Gebhard et al., 1990).
CMTI-III is a 29 amino acid protein of MW 3268 Da that
is found in pumpkin (Curcurbita maxima) seed extracts
(Hojima et al., 1982; McWherter et al., 1989).

It has an

Arg in the active site and inhibits Hageman factor fraction
(jff-factor Xlla) and bovine trypsin (Hojima et al., 1982).
Recombinant Argl5Glu3Iaprotinin is a genetically modified
form of aprotinin (Auerswald et al., 1988) or bovine
pancreatic trypsin inhibitor (BPTI), which normally contains
a Lys at position 15, the PI residue of the active site
(Scott et al., 1987).

BPTI inhibits trypsin, plasmin,

kallikrein, and chymotrypsin (Auerswald et al., 1988).
Arg,5GluMaprotinin inhibited human plasmin, bovine achymotrypsin, porcine pancreatic kallikrein, human plasma
kallikrein, human urinary kallikrein and human anionic and
cationic trypsin (Auerswald et al., 1988).
ozM is a large glycoprotein (subunit MW » 180 kDa) that
usually exists as a tetramer and inhibits a wide range of
plasma proteinases (Arakawa et al., 1989).

The mechanism of

inhibition by OjM is one of stearic hindrance of the
proteinase after cleavage of a bait region in the a2M
molecule by the proteinase which triggers a major
conformational change and results in the "trapping" of the
proteinase (Arakawa et al., 1989; Sottrup-Jensen et al.,
1989).

The "trapped" proteinase is then inaccessible to

large substrates but may still interact with very small
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substrates (Sottrup-Jensen et al., 1989).
a^,

a rat plasma proteinase inhibitor, is similar to

djH except that it is a monomer of MW 190 kDa (Lonberg-Holm
et al., 1987) and has a less efficient trapping mechanism
that is dependent on the ability of a,I3 to form covalent
crosslinks with proteinase Lys residues (Enghild et al.,
1989).
The results of the inhibitor assays showed that both
tryptase isozymes were inhibited by SLPI but were resistant
to inhibition by all other trypsin inhibitors tested. This
may be due, at least in part, to specific structural
characteristics of the isozymes that restrict the activity
of most inhibitors, such as the loop structures (discussed
previously) located on either side of the active site.
These data indicate that there may be other endogenous
inhibitors of tryptase, in addition to heparin, that have
not been examined.
The two tryptase isozymes were also shown to differ
with respect to substrate specificity and rate of activity
on two protein substrates, HMWK and VIP.

Although low-HLT

cleaved HMWK and VIP at 25 and 2 times as fast as high-HLT,
respectively, low-HLT preparations were only 15% active
compared with 95% active high-HLT preparations; thus, lowHLT appears to be less stable than high-HLT.

Low-HLT may,

however, diffuse through the tissues surrounding the site of
mast cell degranulation to a much greater extent than high-
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HLT, giving it a broader range of activity.

Le Trong et al.

(1987) presented data suggesting that the specificity of
chymase may vary according to the presence or absence of
heparin.

Therefore, the difference in substrate specificity

reported on here may be directly related to the difference
in affinity for heparin between the two tryptase isozymes.
Our results confirm the reports that HMWK (Maier et
al., 1983) and VIP (Tam and Caughey, 1990) are substrates
for human tryptase in vitro and show that both human lung
tryptase isozymes degrade these substrates.

Further, high-

HLT and low-HLT differ with respect to the rates and the
primary sites of cleavage on these two natural substrates.
With regard to their activity on HMWK, low-HLT cleaved
HMWK approximately 25 times as fast as high-HLT, when
compared on the basis of the number of active sites.

In

addition, high-HLT cleaved HMWK at a single site in the
light chain, compared with low-HLT, which cleaved the light
chain into several fragments,

similarly, low-HLT cleaved

VIP approximately twice as fast as high-HLT, with the
generation of different cleavage products as monitored by
HPLC.

However, the small VIP molecule appears to be a

better substrate for tryptase than the large HMWK molecule,
since the E:S ratio required for cleavage was much smaller
for VIP (1:17,340 based on the number of active sites of
tryptase) than for HMWK (1:52 with high-HLT and 1:1333 with
low-HLT).

Based on the previously discussed molecular
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modeling studies of tryptase, it has been suggested that
loop structures adjacent to the active site may provide
stearic hindrance for larger molecules (substrates or
inhibitors), making interaction with the active site more
difficult (Johnson and Barton, 1992).
Attempts to determine the primary cleavage site
resulting from the activity of each isozyme on HMWK were
partially successful.

High-HLT produced only two major

cleavage products of 65 kDa and 46 kDa.

Limited amino-

terminal sequencing of the 46 kDa fragment showed that the
major cleavage site is immediately carboxyl to Arg43l, which
is in the histidine-glycine-rich procoagulant region of the
light chain of HMWK*

This supports previous reports that

tryptase destroys the ability of HMWK to participate in the
coagulation cascade (Maier et al., 1983} and the cleavage
site is within the recently identified Zn+1 binding region
of HMWK (DeLa Cadena and Colman, 1992) which is in domain 5
containing the anionic surface binding subdomain (Kunapuli
et al., 1993).

A predicted secondary structure of the light

chain of HMWK by Lottspeich et al. (1985) shows this region
of the molecule as a large loop made up of random coil,
which is additional evidence for the availability of sites
in this region to proteolytic cleavage.

Low-HLT produced

cleavage products of M, 75 kDa and 65 kDa, but lacked the 46
kDa fragment produced by high-HLT.

Western blotting with

antibodies specific for the C-terminal (light chain) region
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of HMWK reacted with only the 46 kDa fragment produced by
high-HLT and with several smaller fragments produced by lowHLT.

Attempts to sequence the two low-HLT generated

fragments of Mr 75 kDa and 65 kDa were unsuccessful,
presumably due to the blocked amino terminus of HMWK.

This

suggests that these two fragments contain the original amino
terminus of the molecule.

Because low-HLT simultaneously

cleaved HMWK at several positions in the C-terminal region,
location of these cleavage positions was not possible.
As previously discussed, prostromelysin (also called
pro-matrix metalloproteinase-3, MMP-3) has also been
reported as a tryptase substrate (Gruber et al., 1988 and
1989).

Tryptase presumably cleaved proMMP-3 to MMP-3 which

then cleaved procollagenase to collagenase.

However,

preliminary data resulting from a collaboration with H.
Nagase (Univ. of Kansas, Lawrence, KS) has indicated that
high-HLT does not cleave proMMP-3, but that low-HLT does.
In addition, a collaboration with 5. Stack (Duke Univ.,
Durham, NC) has produced data indicating that high-HLT
cleaves plasminogen activator and plasmin.

Plasmin is

involved in the dissolution of blood clots by breaking down
fibrin, the major constituent of clots.

The events leading

to clot breakdown involve activation of single-chain
plasminogen activator to two-chain plasminogen activator,
which converts plasminogen to plasmin.

Plasmin has the

capability of activating more plasminogen activator in a
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feedback amplification.

High-HLT has now been shown to

produce plasmin both directly by cleaving plasminogen to
plasmin and indirectly by cleaving single-chain plasminogen
activator to produce two-chain plasminogen activator in
vitro.

These data suggest a possible role of tryptase in

clot dissolution in addition to its potential role in
anticoagulation.

However, the in vivo significance of these

reactions is unclear.
Taken together these findings clearly demonstrate that
there are at least two distinct tryptase isozymes in human
lung tissue that differ in reaction rate and cleavage site
specificity with two natural substrates.

As presented

above, there is also evidence that they may differ in
several other respects, such as heparin binding and
quaternary structure.

The implications of these data

include possible differences in primary structure, radius of
activity and physiological substrates (function),
regulation, carbohydrate content, and even secondary and
tertiary structure.

This view differs from the generally

accepted hypothesis that tryptase exists only as a
heterotetramer in association with heparin, and expands the
study of tryptase to include isozymic forms.

A modified

purification procedure must be used in order to retain lowHLT and to separate the isozymes.

The possible existence of

endogenous inhibitors and/or other forms of regulation of
tryptase other than heparin binding should also be
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investigated further.
The physiological significance of the existence of
these two tryptase isozymes in vivo is not obvious.

Both

isozymes would presumably have the capability to inactivate
HMWK and VIP upon release from mast cells.

It is still

unclear, however, whether one isozyme actually has a more
specific function than the other.

There is notable

variability in the amount of tryptase isolated from lung
tissue obtained at autopsy, but whether this variability is
due to individual differences or other variables, such as
time of death relative to when the tissue was frozen,
remains to be seen.

Both low and high-HLT have been

observed in all our preparations.

It seems likely that

tryptase is of physiological importance given the ubiquitous
distribution of mast cells in the body

and the large amount

of tryptase present in all mast cells.

Mast cells are also

known to participate in certain pathological conditions,
thereby implicating tryptase as a contributing factor in
these conditions.

This points to tryptase as a potential

target of preventive or therapeutic drug therapy.

The

elucidation of the function(s) and regulation of tryptase
and the corresponding mechanisms, therefore, has potentially
important medical benefits.
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APPENDIX

The Appendix contains data that was meaningful but not
of high enough quality to be included in the body of the
dissertation.

These data were included so that people

continuing the tryptase project in the future would have all
data resulting from this project in a collective and
organized form.

The data herein are referred to in the body

of the text and are further explained in the figure legends
accompanying each figure.

Figure 1.

BDS-PAGE (10%) with Reduction of Fools from the

Dowex and Heparin-Sapharose columns.

Lane A, crude lung

extract (25 fil); Lane B, Dowex flowthrough (25 fil); Lane c,
Dowex pool after dialysis (25 fil) ; Lane D, flowthrough from
heparin-Sepharose column (25^1); Lane E, first activity peak
from heparin-Sepharose (5 fig); Lane F, second activity peak
from heparin-Sepharose (5 fig) .

Samples were TCA

precipitated and resuspended in sample buffer before
electrophoresis.

The outside lanes contain MW markers:

phosphorylase B (100 kDa), transferrin (78 kDa), BSA (68
kDa), igG (50 kDa), carbonic anhydrase (29 kDa), soybean
trypsin inhibitor (21 kDa), cytochrome c (12.75 kDa), and
Trasylol (6.5 kDa).
stain.

Protein was visualized with silver

Figure 2.

8DB-PAGE (7%) with Reduction of the Inhibitory

Effects of otjH and

on High-HLT and Trypsin.

Lane A,

HMWK (20 fig; 438 pmol) and high-HLT (3.5 pmol of active
sites); Lane B, HMWK, high-HLT and a2M (3.5 pmol); Lane C,
HMWK, high-HLT and Cjl3 (3.5 fig); Lane D, HMWK (10 ^g); Lane
E, HMWK and trypsin (0.88 pmol); Lane F, HMWK, trypsin and
o2M; Lane G, HMWK, trypsin and c,Ij.

The enzyme (high-HLT or

trypsin) and inhibitor was incubated at RT for 30 minutes
before addition of HMWK, which was incubated at 37°C for 20
minutes before TCA precipitation and gel analysis.

The MW

standards in the outside lanes are the same as in Figure 1.
Protein was visualized with colloidal Coomassie blue.
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Figure 3-A.

SDS-PAGE (7%) with Reduction of Laminin,

Fibrinogen and Fibroneotin after Exposure to High-HLT.

Lane

A, laminin (13.4 fig, 13.4 pmol); Lane B, laminin and highHLT (0.07 pmol); Lane C, fibrinogen (13.4 fig, 39.4 pmol);
Lane D, fibrinogen and high-HLT (0.20 pmol); Lane E,
fibroneotin (13.4 fig, 26.8 pmol); Lane F, fibroneotin.and
high-HLT (0.13 pmol).

The E:S ratio in each case was 1:200

based on protein concentration.
as in Figure 1.
Coomassie blue.

MW standards are the same

Proteins were visualized with colloidal
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Figure 3-B.

SDS-PAGE (4-20%) with Reduction of Lauinin,

Fibrinogen end Fibroneotin after Exposure to High-HLT.

This

gel was a duplicate of Figure 3-A except that half the
amount of protein was loaded in each lane and the gel was
developed with silver stain.
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Figure 4-A.

SDS-page (10%) with Reduction of the cleavage

of HMWK by High-HLT Without Precipitation Prior to
Electrophoresis.

Lane A, HMWK at zero minutes (2 fig, 17.8

pmol); Lane B, HMWK and high-HLT (0.04 pmol) after a 5
minute incubation at RT; Lane C, 10 minutes; Lane D, after
20 minutes; Lane E, 40 minutes; Lane F, after 60 minutes;
Lane G, after 90 minutes.
protein concentration.

The E:S ratio was 1:50 based on

MW standards were as in Figure 1 and

proteins were visualized with silver stain.
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Figure 4-B.

BDS-PAQB (10%) with Reduction of the Cleavage

of HMWK by Lov-HLT Without Precipitation Prior to
Electrophoresis.

This gel was performed as in Figure 4-A

except that 0.01 pmol of low-HLT was used per sample instead
of 0.04 pmol of high-HLT and Lane A contained HMWK after 90
minutes at RT, pH 7.5.
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